

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

28 July 2022 (28.07.2022)



(10) International Publication Number

WO 2022/157656 A1

(51) International Patent Classification:

C07D 213/81 (2006.01) A61P 31/12 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2022/050463

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

20 January 2022 (20.01.2022)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/139,696 20 January 2021 (20.01.2021) US

(71) Applicant: INDIAN INSTITUTE OF SCIENCE

[IN/IN]; Sir C V Raman Road, Bangalore, Karnataka 560012 (IN).

(72) Inventors: TRIPATHI, Shashank; D221, Faculty Quarters, Indian Institute of Science, Bengaluru, Karnataka 560012 (IN). NARAYAN, Rohan; No.2, Chithranilaya, Rudra Compound, Mathikere, Bengaluru, Karnataka 560054 (IN). BIJI, Abhijith; N220, N-block Hostel, Indian Institute of Science, Bengaluru, Karnataka 560012 (IN). R.S., Rajmani; Ramaiah, 214, 6th main, Gokul 1st stage, 2nd phase, Mathikere, Bangalore, Karnataka 560054 (IN).

(74) Agent: J., Vikas et al.; K&S Partners | Intellectual Property Attorneys, 4121/B, 6th Cross, 19A Main, HAL II Stage (Extension), Bangalore 560038 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIVIRAL APPLICATIONS OF PICOLINIC ACID AND ITS DERIVATIVES

(57) Abstract: The present disclosure provides methods for inhibiting entry of a virus into a host cell using picolinic acid or a salt or derivative thereof. The present disclosure also provides methods for treating or preventing a viral infection in a subject by administering picolinic acid or a salt or derivative thereof. In particular, the methods of the present disclosure are effective for enveloped viruses and syncytium-forming viruses. In some embodiments, the present disclosure provides methods of treating or preventing a SARS CoV-2, Influenza A virus, human parainfluenza virus, herpes simplex virus, Japanese encephalitis virus, Zika virus, or a flavivirus infection.



WO 2022/157656 A1

ANTIVIRAL APPLICATIONS OF PICOLINIC ACID AND ITS DERIVATIVES**CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] The present application claims the benefit of priority to U.S. Provisional Application
5 No. 63/139,696, filed on January 20, 2021.

FIELD OF THE DISCLOSURE

[0002] The present invention relates to methods and compositions for treating or preventing
viral infections. In particular, the present invention relates to use of picolinic acid or a salt or
derivative thereof or compositions comprising said compounds for treating or preventing viral
10 infections caused by enveloped viruses such as SARS-CoV-2 virus, influenza virus,
parainfluenza virus, herpes simplex virus, Zika virus, or Japanese encephalitis virus and other
enveloped viruses.

BACKGROUND OF THE DISCLOSURE

[0003] Virus infections pose a major challenge for public health systems throughout the world.
15 Despite rapid scientific progress in the field of virology, the lack of effective therapeutic
options and vaccines for most viral infectious diseases continues to take its toll. Emerging viral
diseases pose a major threat primarily because of their rapid transmission rates and the inherent
difficulties associated with developing effective vaccines and treatment options against such
novel pathogens in a short span of time. The SARS CoV-2 pandemic ongoing at the time of
20 filing this application which has resulted in worldwide 31 million confirmed cases to date is a
perfect example of such a major threat. Hence there is a need to develop broad-spectrum
antiviral compounds that are effective against multiple viruses. Majority of currently available
antivirals target one or more components directly associated with the virus life cycle. Hence
the activity tends to be limited to closely related viruses, often within the same virus family.
25 Select nucleoside analogues including cidofovir, favipiravir and ribavirin have shown to be
effective against a broad range of viruses but pose a major risk of developing antiviral
resistance mainly among RNA viruses. An ideal approach to circumvent such drawbacks
associated with pathogen-specific antivirals is the use of host-targeting drugs, which both
minimize the risk of virus-drug resistance and improves the spectrum of activity against
30 multiple viruses across different virus families.

SUMMARY OF THE DISCLOSURE

[0004] The present disclosure provides a method for inhibiting entry of a virus into a host cell, comprising contacting the host cell with picolinic acid or a salt or derivative thereof. In some embodiments, the virus is an enveloped virus. In some embodiments, the virus is a syncytium-forming virus. In some embodiments, the virus is SARS-CoV-2, influenza, parainfluenza, herpes simplex virus (HSV), Japanese Encephalitis virus (JEV), Zika virus, or a flavivirus.

[0005] The present disclosure provides a method for treating or preventing a viral infection in a subject, comprising administering to the subject picolinic acid or a salt or derivative thereof. In some embodiments, the viral infection is caused by an enveloped virus. In some embodiments, the viral infection is caused by a syncytium-forming virus. In some embodiments, the viral infection is caused by SARS-CoV-2, parainfluenza, influenza, HSV, JEV, Zika virus, or a flavivirus.

[0006] The present disclosure provides picolinic acid or a salt or derivative thereof for use in inhibiting entry of a virus into a host cell. In some embodiments, the virus is an enveloped virus. In some embodiments, the virus is a syncytium-forming virus. In some embodiments, the virus is SARS-CoV-2, parainfluenza, influenza, HSV, JEV, Zika virus, or a flavivirus.

[0007] The present disclosure provides picolinic acid or a salt or derivative thereof for use as a medicament for treating or preventing a viral infection in a subject. In some embodiments, the viral infection is caused by an enveloped virus. In some embodiments, the viral infection is caused by a syncytium-forming virus. In some embodiments, the viral infection is caused by SARS-CoV-2, parainfluenza, influenza, HSV, JEV, Zika virus, or a flavivirus.

[0008] The present disclosure also provides compositions comprising picolinic acid or a salt or derivative thereof and a suitable excipient or carrier. In some embodiments, the present disclosure provides an oral, parenteral, intranasal, or inhalational pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient. In some embodiments, the present disclosure provides a dietary supplement comprising picolinic acid or a salt or derivative thereof and a suitable excipient or carrier. In some embodiments, the present disclosure provides a plant formulation comprising picolinic acid or a salt or derivative thereof and a suitable excipient or carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] **FIG. 1A** shows results of a cell viability study using increasing concentration of picolinic acid. **FIG. 1B** shows results of the luminescence assay for cells infected with firefly luciferase expressing influenza A virus, parainfluenza virus, and HSV-1 virus in the presence or absence of picolinic acid. **FIG. 1C** shows a Western blot analysis of a cell lysate obtained from VeroE6 cells infected with Japanese Encephalitis Virus in the presence or absence of picolinic acid.

[0010] **FIG. 2A** shows results of an immunofluorescence assay of cells infected with influenza A virus in the presence or absence of picolinic acid at 3 hours post-infection. **FIG. 2B** shows results of an immunofluorescence assay of cells infected with influenza A virus in the presence or absence of picolinic acid at 9 hours post-infection. **FIG. 2C** shows a graph of a total number of nucleoprotein (NP) positive cells against untreated virus control for three different conditions. **FIG. 2D** shows a Western blot analysis of cell lysates obtained from three different conditions for the expression of influenza A virus NP.

[0011] **FIG. 3A** shows percent weight loss in mice upon treatment of mice with 20 or 100 mg of picolinic acid. **FIG. 3B** shows percent weight loss in mice infected with influenza A virus and pre-treated with picolinic acid and vehicle-treated mice.

[0012] **FIG. 4A** shows survival rate of mice infected with influenza A virus and pre-treated with picolinic acid and vehicle-treated mice. **FIG. 4B** shows viral titer in mice pre-treated with picolinic acid and vehicle-treated mice.

[0013] **FIG. 5A** shows different steps involved in the production of pseudotyped SARS CoV-2 particles. **FIG. 5B** shows results of a luminescence assay of cells infected with pseudotyped SARS CoV-2 particles in presence of picolinic acid, chloroquine (CQ), and camostat mesylate (CM).

[0014] **FIG. 6** shows results of a qRT-PCR assay showing viral RNA load in three different cells infected with SARS-CoV-2 in the presence or absence of picolinic acid.

[0015] **FIG. 7: Panel A** shows results of a qRT-PCR assay showing viral RNA copy numbers in HEK ACE2 cells pre-treated for 3hr with increasing doses of PA as indicated and infected with 0.1 MOI of SARS-CoV-2 Hong Kong. **Panel B** shows results of a qRT-PCR assay showing viral RNA copy numbers in HEK ACE2 cells pre-treated for 3hr with 2mM PA and

infected with 0.1 MOI of four SARS-CoV-2 variants of concern. **Panel C** shows results of a qRT-PCR assay showing viral RNA copy numbers in VeroE6 cells pre-treated for 3hr with increasing doses of PA as indicated and infected with 0.001 MOI of SARS-CoV-2 Hong Kong. **Panel D** shows results of a qRT-PCR assay showing viral RNA copy numbers in VeroE6 cells pre-treated for 3hr with 2mM PA and infected with 0.001 MOI of four SARS-CoV-2 variants of concern. **Panel E** shows results of a qRT-PCR assay showing viral RNA copy numbers in VeroE6, HEK ACE2 and Calu3 cells pre-treated with 2mM PA and infected with 0.1 MOI SARS-CoV-2 for 48hr. **Panel F** shows results of a plaque assay of supernatants of MDCK cells pre-treated with increasing concentrations of PA and infected with 0.01MOI of PR8 wild type virus for 48hr. **Panels G-J** show luciferase assay data for A549 cells pre-treated with 2mM PA and infected with different luciferase reporter viruses for 48hr. **Panels K and L** show a western blot analysis of flavivirus envelope protein showing the inhibition of Japanese encephalitis Virus (JEV) clinical strain P20778, and wild type Zika virus (ZIKV) Cambodia strain.

[0016] **FIG. 8: Panel A** shows a schematic for a prophylactic PA treatment regimen in hamsters. **Panel B** shows a schematic for a therapeutic PA treatment regimen in hamsters. **Panel C** shows viral RNA copy numbers from lung tissue homogenates for both prophylactic and therapeutic treatment groups. **Panel D** shows corresponding total lung weight loss percentage up to 4 days post-infection. **Panel E** shows percentage bodyweight loss in the prophylactic treatment group. **Panel F** shows percentage bodyweight loss in the therapeutic treatment group. **Panel G** shows images of lungs showing pathology in mock and recovery in prophylactic and therapeutic treatment groups. **Panel H** shows histology images for all treatment groups including mock infected and healthy controls. **Panel I** shows scores for histology sections for all treatment groups.

[0017] **FIG. 9: Panel A** shows a schematic showing toxicity and infection/treatment schedule of PA administration via oral or IP routes in BALB/c mice. **Panel B** shows toxicity results with bodyweight changes over 9 days post treatment with 20mg/kg and 100 mg/kg PA delivered via IP route. **Panel C** shows bodyweight changes over 9 days post treatment with 20mg/kg and 100 mg/kg PA delivered via oral route. **Panel D** shows a plaque assay quantification of infectious virus titer from lungs. **Panel E** shows percentage survival of BALB/c mice for both prophylactic and therapeutic treatment groups via IP and oral routes. **Panel F** shows body weight loss in BALB/c mice up to day 7 post infection both prophylactic and therapeutic treatment groups via IP and oral routes. **Panel G** shows histology images for prophylactic oral,

therapeutic oral and therapeutic IP groups, including mock infected and healthy controls. **Panel H** shows scores for histology sections for these groups.

[0018] **FIG. 10:** **Panel A** shows IFA (immunofluorescence assay) images for HEK ACE2 cells labelled with virus spike protein. **Panel B** shows quantification of spike positive HEK ACE2 cells. **Panel C** shows corresponding western blot data. **Panel D** shows IFA images for VeroE6 cells labelled with virus spike protein. **Panel E** shows quantification of spike positive VeroE6 cells. **Panel F** shows corresponding western blot data. **Panel G** shows results of firefly luciferase assay of HEK ACE2 cells pre-treated with increasing concentrations of PA and infected with SARS-CoV-2 spike pseudotyped particles and harvested 60hr later. **Panel H** shows IFA images of A549 cells labelled with influenza virus nucleocapsid protein (NP). **Panel I** shows quantification of NP positive A549 cells. **Panel J** shows corresponding western blot data.

[0019] **FIG. 11:** **Panel A, left side** shows IFA images of VeroE6 cells transfected with a plasmid expressing SARS-CoV-2 spike, 3hr later treated with increasing concentrations of PA, and 24hr later, fixed and labelled with WGA and DAPI to label cell membrane and nuclei respectively. **Panel A, right side graph** shows area of syncytia quantified using ImageJ/Fiji software and plotted as percentage of untreated control. **Panel B** shows a graph of fluorescence intensity measurements of A549 cells pre-treated with 2mM PA, 10 μ M NH₄Cl or 10 μ M CQ, infected with R18 labelled PR8 WT virus, and transferred to a plate reader at 37°C for fluorescence intensity measurements at 10 min intervals. **Panel C** shows the percentage of Tf647 positive A549 cells, where the A549 cells were pre-treated with 2mM PA, pulsed with 25 μ g/mL Tf647 for 1hr in the presence of PA, washed and analyzed by flow cytometry to quantify the percentage of Tf647 positive cells. **Panel D** shows confocal microscopic images of PA treated VeroE6 cells incubated with Tf647 and 100MOI PR8 WT virus for 1hr and fixed with 4% formalin. **Panel E** shows distance of Tf647 labelled vesicles from nuclei, as quantified using ImageJ/Fiji. **Panel F** shows TEM images of PR8 WT virus particles incubated with 2mM PA, 0.01% Triton X100 or distilled water for 3hr, mounted on copper grids and stained with uranyl acetate.

[0020] **FIG. 12:** **Panel A** shows quantification of Coxsackie virus B3 infection in HeLa cells by western blot using VP1 antibody. **Panel B** shows a plaque assay quantification of HeLa cells pre-treated with increasing concentrations of PA and infected with 0.1 MOI CVB3. **Panel C, left side** shows IFA images of HEK cells pre-treated with 2mM PA, infected with Rota virus

RRV strain, fixed with 4% formalin after 12hr and immunolabelled with VP6 antibody and DAPI to label the virus particles and nuclei respectively. **Panel C, right side** shows percentage positive cells quantified using ImageJ/Fiji. **Panel D** shows GFP positive HEK cells measured by flow cytometry where HEK cells were pre-treated with 2mM PA and infected with AAV6-GFP particles in the presence of PA at different volumes. **Panel E** shows GFP positive HEK cells measured by flow cytometry where HEK cells were pre-treated with 2mM PA and infected with AAV5-GFP particles. **Panel F** shows spectrophotometric quantification of *M. smegmatis* cells treated with increasing concentrations of PA. **Panel G** shows spectrophotometric quantification of 7H9 broth inoculated with 100 μ L of log phase secondary bacterial culture, treated with 1mM PA at regular time intervals, and inoculated with 10 MOI TM4 mycobacteriophage during mid-log phase.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0021] With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The use of the expression “at least” or “at least one” suggests the use of one or more elements or ingredients or quantities, as the use may be in the embodiment of the disclosure to achieve one or more of the desired objects or results. Throughout this specification, the word “comprise”, or variations such as “comprises” or “comprising” or “containing” or “has” or “having”, or “including but not limited to” wherever used, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0022] Reference throughout this specification to “one embodiment”, “an embodiment”, or “some embodiments” means that a particular feature, structure or characteristic described in connection with the embodiment may be included in at least one embodiment of the present disclosure. Thus, the appearances of the phrases “in one embodiment”, “in an embodiment”, or “in some embodiments” in various places throughout this specification may not necessarily all refer to the same embodiment. It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are,

for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination.

[0023] The term “subject” or “host” as used herein refers to a plant or an animal including humans, livestock animals, other primates (*e.g.*, chimpanzees and other apes and monkey species), domestic mammals (*e.g.*, dogs and cats), and laboratory animals (*e.g.*, rodents such as mice, rats, and guinea pigs). The term “livestock” includes, but is not limited to, cattle (cows, buffaloes), horses, deer, sheep, goats, swine, poultry (including egg-producing poultry), elk, reindeer, bison, llamas, alpacas, fish, etc. In some embodiments, the subject or host is a mammal, bird, or a plant. In some embodiments, the subject is a human.

[0024] Picolinic acid (PA), also known as pyridine-2-carboxylic acid (IUPAC), is an endogenous metabolite of tryptophan in humans and is synthesized via the kynurenine pathway. It has been shown to exhibit various neuroprotective and anti-inflammatory effects in the body.

[0025] For any viral pathogen, infectious cycle begins with an entry into the host cell. For this step, many viruses exploit cellular endocytosis machinery or fuse at the cell membrane to deliver a viral genome inside the cells. The present inventors have found that picolinic acid interferes with and inhibits a virus entry into a host cell as well as early events associated with the virus entry for a range of viruses such as SARS-CoV-2, parainfluenza, influenza, HSV, Zika, and JEV. In particular, the present inventors have found that picolinic acid inhibits the viral entry at the step of endocytosis or membrane fusion. Since this is a shared step for a range of viral pathogens, picolinic acid can serve as a broad-spectrum antiviral compound for a range of viruses. Accordingly, the present disclosure provides methods for inhibiting a virus entry into a host cell and methods of treating and/or preventing viral infections in a subject by administering picolinic acid or a salt or derivative thereof.

[0026] In some embodiments, the present disclosure provides a method for inhibiting entry of a virus into a host cell, comprising contacting the host cell with picolinic acid or a salt or derivative thereof. In some embodiments, said contact is active (*e.g.*, picolinic acid or a salt or derivative thereof is administered directly to target cells) or passive (*e.g.*, picolinic acid or a salt or derivative thereof is administered to a subject and the administered compound reaches the target cell).

[0027] In some embodiments, the present disclosure provides a method for treating or preventing a viral infection in a subject, comprising administering to the subject picolinic acid or a salt or derivative thereof.

[0028] In some embodiments, the methods of the disclosure prevent entry of enveloped viruses into the host cell or treat and/or prevent infections caused by enveloped viruses. In some embodiments, the methods of the disclosure prevent entry of or treat or prevent infections caused by enveloped viruses having a single-stranded RNA genome into the host cell. In some embodiments, the methods of the disclosure prevent entry of or treat or prevent infections caused by enveloped viruses having a negative sense, single-stranded RNA genome into the host cell. In some embodiments, the methods of the disclosure prevent entry of or treat or prevent infections caused by enveloped viruses having a positive sense, single-stranded RNA genome into the host cell. In some embodiments, the methods of the disclosure prevent entry of or treat or prevent infections caused by enveloped viruses having a double-stranded DNA genome into the host cell. In some embodiments, the methods of the present disclosure are effective against enveloped viruses selected from the group consisting of SARS-CoV-2, parainfluenza, influenza, Japanese encephalitis virus (JEV), herpes simplex virus (HSV), Zika virus, or a flavivirus. In some embodiments, the methods of the disclosure prevent entry of syncytium-forming viruses into a host cell or treat or prevent infections caused by these viruses. The term “syncytium-forming” or “syncytia-forming” viruses as used herein refers to viruses that mediate fusion of an infected host cell with neighboring cells leading to the formation of multi-nucleate enlarged cells called syncytia. In some embodiments, the present methods are effective against syncytium-forming viruses which include, but are not limited to, viruses of family - Coronaviridae (e.g., SARS-CoV-2, MERS, SARS-CoV etc.), Herpesviridae (HSV, HCMV etc.), Paramyxoviridae (Nipah, Hendra, Measles, RSV etc.), Retroviridae (HIV, HTLV etc.), Hepatitis C Virus, Ebola, Sendai, Reovirus (e.g., Orthoreoviruses and Aquareoviruses).

[0029] The present disclosure encompasses all variants, strains, serotypes, wild-type, and mutant versions of the viruses disclosed herein.

[0030] In some embodiments, picolinic acid or a salt or derivative thereof is administered to the subject before entry of virus particles. In some embodiments, picolinic acid or a salt or derivative thereof is administered to the subject after entry of virus particles.

[0031] In some embodiments, the host cell is contacted with or the subject is administered with picolinic acid. In some other embodiments, the host cell is contacted with or the subject is administered with a salt or derivative of picolinic acid. In some embodiments, salts of picolinic acid include, but are not limited to, zinc picolinate, chromium picolinate, iron picolinate, sodium picolinate, and the like. In some embodiments, a derivative of picolinic acid is fusaric acid. In some embodiments, derivatives of picolinic acid include compounds synthesized by introducing substitutions at the 3, 4, 5 and/or 6 positions of picolinic acid.

[0032] Picolinic acid in moderate amounts is not cytotoxic to host cells; however, is effective in inhibiting entry of viruses into the host cells.

[0033] In some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject inhibits entry of a virus into cells of the subject. Accordingly, in some embodiments, administration of picolinic acid or a salt or derivative thereof prevents the virus from establishing an active infection in the subject. The term “active infection” as used herein refers to a condition where the subject is exhibiting and/or suffering from symptoms of the infection. For example, in some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject does not allow a build-up of viral titer in the subject, compared to a subject to whom picolinic acid or a salt or derivative thereof is not administered.

[0034] In embodiments where picolinic acid or a salt or derivative thereof is administered to a subject after entry of virus particles into cells of the subject, picolinic acid or a salt or derivative thereof inhibits entry of progeny virus particles into cells of the subject.

[0035] The terms “inhibits entry of a virus into cells of the subject” and “inhibits entry of a virus into a host cell” as used herein encompass inhibition of viral entry at the step of endocytosis or membrane fusion (syncytia formation) as well as other early events associated with entry of viruses into cells. Certain viruses enter a host cell via a process called receptor-mediated endocytosis. Some viruses enter the host cell via a direct membrane fusion where the envelope of the virus fuses with the cellular membrane. The present inventors found that picolinic acid inhibits both types of entry events, receptor-mediated endocytosis as well as viral-cellular membrane fusion. Further, after entry into the host cell, certain viruses induce fusion of infected host cell with neighboring cells – a process called syncytia-formation. The present inventors found that picolinic acid inhibits virus-induced syncytia formation. The present inventors also found that picolinic acid disrupts the integrity of viral envelope. Thus,

picolinic acid exerts antiviral effects through inhibition of various early events associated with a virus entry into a host cell and can serve as a broad-spectrum inhibitor of viruses, particularly enveloped viruses and syncytium-forming viruses.

[0036] In some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject reduces the viral titer in the subject. In some embodiments, the viral titer of the subject is reduced by about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or almost about by 100%, compared to the viral titer prior to administration of picolinic acid or a salt or derivative thereof.

[0037] In some embodiments, upon administration of picolinic acid or a salt or derivative thereof, the viral titer of the subject is reduced by about 10-99%, 10-95%, 10-90%, 10-85%, 10-80%, 10-75%, 10-70%, 10-65%, 10-60%, 10-55%, 10-50%, 10-45%, 10-40%, 10-35%, 10-30%, 10-25%, 10-20%, 20-90%, 20-80%, 20-75%, 20-70%, 20-65%, 20-60%, 20-55%, 20-50%, 20-45%, 20-40%, 20-35%, 20-30%, 25-90%, 25-85%, 25-80%, 25-75%, 25-70%, 25-65%, 25-60%, 25-55%, 25-50%, 25-45%, 25-40%, 25-35%, 30-90%, 30-85%, 30-80%, 30-75%, 30-70%, 30-65%, 30-60%, 30-55%, 30-50%, 30-45%, 30-40%, 35-90%, 35-85%, 35-80%, 35-75%, 35-70%, 35-65%, 35-60%, 35-55%, 35-50%, 35-45%, 40-90%, 40-85%, 40-80%, 40-75%, 40-70%, 40-65%, 40-60%, 40-55%, 40-50%, 45-90%, 45-85%, 45-80%, 45-75%, 45-70%, 45-65%, 45-60%, 45-55%, 45-50%, 50-90%, 50-85%, 50-80%, 50-75%, 50-70%, 50-65%, 50-60%, 55-90%, 55-85%, 55-80%, 55-75%, 55-70%, 55-65%, 60-90%, 60-85%, 60-80%, 60-75%, 60-70%, 65-90%, 65-85%, 65-80%, 65-75%, 70-90%, 70-85%, 70-80%, 75-90%, 75-85%, or 80-90%, including values and ranges thereof, compared to the viral titer prior to administration of picolinic acid or a salt or derivative thereof.

[0038] In some embodiments, upon administration of picolinic acid or a salt or derivative thereof, the viral titer of the subject is reduced by about 25-90%, 25-75%, 25-60%, 25-50%, 30-90%, 30-70%, 30-60%, 40-90%, 40-80%, 40-75%, 40-70%, 40-60%, 50-90%, 50-80%, 50-75%, 60-90%, 60-80%, or 70-90%, including values and ranges thereof, compared to the viral titer prior to administration of picolinic acid or a salt or derivative thereof.

[0039] In some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject reduces the viral titer of the subject by about 2.5-fold, 4-fold, 5-fold, 7-fold, 8-fold, 9-fold, 10-fold, 12-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, or by about 50-fold, compared to the viral titer prior to administration of picolinic acid or a salt or derivative thereof.

In some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject reduces the viral titer of the subject by about 5-40 fold, 5-30 fold, 5-25 fold, 5-20 fold, 5-15 fold, 10-40 fold, 10-30 fold, 10-25 fold, or by about 10-20 fold, compared to the viral titer prior to administration of picolinic acid or a salt or derivative thereof.

- 5 [0040] In some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject, suffering from an infection caused by SARS-CoV-2 virus, parainfluenza virus, influenza virus, HSV, JEV, Zika virus, or a flavivirus reduces titer of the respective virus in the subject by any of the values and ranges described herein.

- 10 [0041] In some embodiments, administration of picolinic acid or a salt or derivative thereof to a subject facilitates recovery of the subject from a viral infection compared to a subject not administered with picolinic acid or a salt or derivative thereof. For example, a subject administered with picolinic acid or a salt or derivative thereof experiences no or less loss of weight upon viral infection compared to a subject not administered with picolinic acid or a salt or derivative thereof.

- 15 [0042] In some embodiments, picolinic acid or a salt or derivative thereof is administered to a subject orally, parenterally, topically, intranasally, via inhalation, and/or via nebulization.

- [0043] In some embodiments, picolinic acid or a salt or derivative thereof is administered orally. Oral administration comprises swallowing, so that picolinic acid or a salt or derivative enters the gastrointestinal tract, or buccal or sublingual administration by which picolinic acid or a salt or derivative enters the blood stream directly from the mouth. Accordingly, the present disclosure contemplates an oral pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient.
- 20

- [0044] In some embodiments, picolinic acid or a salt or derivative is administered parenterally via injection or infusion. In parenteral administration, picolinic acid or a salt or derivative is administered directly into the blood stream or into muscles. Suitable means for parenteral administration include intravenous, intrathecal, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques. Accordingly, the present disclosure contemplates a parenteral pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient.
- 25
- 30

- [0045] In some embodiments, picolinic acid or a salt or derivative thereof is formulated for topical administration to the skin or mucosa (i.e., dermally or transdermally) leading to systemic absorption of picolinic acid or a salt or derivative thereof. Accordingly, in some embodiments, provided herein is a topical pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient for preventing entry of a virus into the skin cells of a subject. In some embodiments, a topical formulation comprises picolinic acid or a salt or derivative thereof in an amount of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or about 50%, including values and ranges thereof, by weight of the formulation. In some embodiments, a topical formulation comprises picolinic acid or a salt or derivative thereof in an amount of about 5-50%, about 5-40%, about 5-30%, about 5-25%, about 5-20%, about 5-15%, about 10-50%, about 10-40%, about 10-30%, about 10-25%, about 10-20%, about 15-50%, about 15-40%, about 15-35%, about 15-30%, about 15-25%, about 20-50%, about 20-40%, about 20-30%, about 25-50%, about 25-40%, about 30-50%, about 30-45%, or about 40-50%, including values and ranges thereof, by weight of the formulation.
- [0046] In some embodiments, picolinic acid or a salt or derivative is formulated for administration intranasally, by inhalation, or by nebulization. Accordingly, the present disclosure contemplates a pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient for intranasal or inhalational administration or administration by nebulization. In some embodiments, a composition for intranasal or inhalational administration or administration by nebulization comprises picolinic acid or a salt or derivative thereof at a concentration of about 0.01 mM to about 50 mM, about 0.01 mM to about 40 mM, about 0.01 mM to about 35 mM, 0.01 mM to about 30 mM, about 0.01 mM to about 25 mM, about 0.01 mM to about 20 mM, about 0.01 mM to about 15 mM, about 0.01 mM to about 10 mM, about 0.05 mM to about 50 mM, about 0.05 mM to about 45 mM, about 0.05 mM to about 40 mM, about 0.05 mM to about 35 mM, about 0.05 mM to about 30 mM, about 0.05 mM to about 25 mM, about 0.05 mM to about 20 mM, about 0.05 mM to about 15 mM, about 0.05 mM to about 10 mM, about 1 mM to about 50 mM, about 1 mM to about 40 mM, about 1 mM to about 35 mM, about 1 mM to about 30 mM, about 1 mM to about 25 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 2.5 mM to about 50 mM, about 2.5 mM to about 40 mM, about 2.5 mM to about 35 mM, about 2.5 mM to about 30 mM, about 2.5 mM to about 25 mM, about 2.5 mM to about 20 mM, about 2.5 mM to about 15 mM, about 2.5 mM to about 10 mM, about 5 mM to about 50 mM, about 5 mM to about 45 mM, about 5 mM to about 40 mM, about 5 mM to about 35

- mM, about 5 mM to about 30 mM, about 5 mM to about 30 mM, about 5 mM to about 25 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 10 mM to about 50 mM, about 10 mM to about 45 mM, about 10 mM to about 40 mM, about 10 mM to about 35 mM, about 10 mM to about 30 mM, about 10 mM to about 25 mM, about 15 mM to about 50 mM, about 15 mM to about 45 mM, about 15 mM to about 40 mM, about 15 mM to about 30 mM, about 20 mM to about 50 mM, about 20 mM to about 45 mM, about 20 mM to about 40 mM, about 20 mM to about 30 mM, about 25 mM to about 50 mM, about 25 mM to about 45 mM, about 25 mM to about 40 mM, or about 30 mM to about 50 mM, including values and ranges thereof.
- 10 [0047] In some embodiments, a composition for intranasal or inhalational administration or administration by nebulization comprises picolinic acid or a salt or derivative thereof at a concentration of about 0.01 mM, 0.05 mM, 1 mM, 2.5 mM, 5 mM, 7.5 mM, 10 mM, 12.5 mM, 15 mM, 18 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, or about 50 mM, including values and ranges therebetween.
- 15 [0048] The dosage regimen for picolinic acid or a salt or derivative thereof and/or compositions containing picolinic acid or a salt or derivative thereof is based on a variety of factors, such as, age, weight, sex and medical condition of the patient; and the route of administration. In some embodiments, systemic dosage for picolinic acid or a salt or derivative thereof can range from about 1 mg to about 100 mg, including values and ranges thereof, per kilogram of body weight
- 20 per day. In some embodiments, systemic dosage for picolinic acid or a salt or derivative thereof can range from about 3 mg to about 100 mg, about 3 mg to about 90 mg, about 3 mg to about 80 mg, about 3 mg to about 75 mg, about 3 mg to about 70 mg, about 3 mg to about 60 mg, about 3 mg to about 50 mg, about 3 mg to about 45 mg, about 3 mg to about 40 mg, about 3 mg to about 30 mg, about 3 mg to about 25 mg, about 5 mg to about 100 mg, about 5 mg to about 90 mg, about 5 mg to about 80 mg, about 5 mg to about 75 mg, about 5 mg to about 70 mg, about 5 mg to about 60 mg, about 5 mg to about 50 mg, about 5 mg to about 45 mg, about 5 mg to about 40 mg, about 5 mg to about 30 mg, about 5 mg to about 25 mg, about 10 mg to about 100 mg, about 10 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 75 mg, about 10 mg to about 70 mg, about 10 mg to about 60 mg, about 10 mg to about 50 mg,
- 25 about 10 mg to about 45 mg, about 10 mg to about 40 mg, about 10 mg to about 30 mg, about 10 mg to about 25 mg, about 20 mg to about 100 mg, about 20 mg to about 90 mg, about 20 mg to about 80 mg, about 20 mg to about 75 mg, about 20 mg to about 70 mg, about 20 mg to
- 30

about 60 mg, about 20 mg to about 50 mg, about 20 mg to about 40 mg, about 25 mg to about 100 mg, about 25 mg to about 90 mg, about 25 mg to about 80 mg, about 25 mg to about 75 mg, about 25 mg to about 70 mg, about 25 mg to about 60 mg, about 25 mg to about 50 mg, about 30 mg to about 100 mg, about 30 mg to about 90 mg, about 30 mg to about 80 mg, about 30 mg to about 75 mg, about 30 mg to about 70 mg, about 30 mg to about 60 mg, about 30 mg to about 50 mg, about 40 mg to about 100 mg, about 40 mg to about 90 mg, about 40 mg to about 80 mg, about 40 mg to about 75 mg, about 40 mg to about 70 mg, about 40 mg to about 60 mg, about 50 mg to about 100 mg, about 50 mg to about 90 mg, about 50 mg to about 80 mg, about 50 mg to about 75 mg, about 50 mg to about 70 mg, about 60 mg to about 100 mg, about 60 mg to about 90 mg, about 60 mg to 80 mg, about 70 mg to about 100 mg, about 70 mg to about 90 mg, or about 80 mg to about 100 mg, including values and ranges thereof, per kilogram of body weight per day. In some embodiments, a total daily dose for picolinic acid or a salt or derivative thereof is about 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 8 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, or about 100 mg, including values and ranges thereof, per kilogram of body weight.

[0049] In some embodiments, total daily dose for picolinic acid or a salt or derivative thereof can range from about 200 mg to about 2000 mg, about 200 mg to about 1800 mg, about 200 mg to about 1600 mg, about 200 mg to about 1500 mg, about 200 mg to about 1400 mg, about 200 mg to about 1200 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 700 mg, about 200 mg to about 600 mg, about 200 mg to about 500 mg, about 200 mg to about 400 mg, about 300 mg to about 2000 mg, about 300 mg to about 1800 mg, about 300 mg to about 1600 mg, about 300 mg to about 1400 mg, about 300 mg to about 1200 mg, about 300 mg to about 1000 mg, about 300 mg to about 800 mg, about 300 mg to about 600 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1500 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 700 mg, about 500 mg to about 2000 mg, about 500 mg to about 1800 mg, about 500 mg to about 1600 mg, about 500 mg to about 1500 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 500 mg to about 2000 mg, about 500 mg to about 1800 mg, about 500 mg to about 1600 mg, about 500 mg to about 1500 mg, about 500 mg to about 1400 mg, about 500 mg to about 1200 mg, about 500 mg to about 1000 mg, about 500 mg to about 800 mg, about 600 mg to about 2000 mg, about 600 mg to about 1800 mg, about 600 mg to about 1600 mg,

about 600 mg to about 1500 mg, about 600 mg to about 1400 mg, about 600 mg to about 1200 mg, about 600 mg to about 1000 mg, about 700 mg to about 2000 mg, about 700 mg to about 1800 mg, about 700 mg to about 1600 mg, about 700 mg to about 1500 mg, about 700 mg to about 1400 mg, about 700 mg to about 1200 mg, about 700 mg to about 1000 mg, about 800 mg to about 2000 mg, about 800 mg to about 1800 mg, about 800 mg to about 1600 mg, about 800 mg to about 1500 mg, about 800 mg to about 1400 mg, about 800 mg to about 1200 mg, about 1000 mg to about 2000 mg, about 1000 mg to about 1800 mg, about 1000 mg to about 1500 mg, about 1200 mg to about 2000 mg, about 1200 mg to about 1800 mg, about 1400 mg to about 2000 mg, about 1500 mg to about 2000 mg, including values and ranges thereof, per kilogram of body weight per day. In some embodiments, a total daily dose for picolinic acid or a salt or derivative thereof is about 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, or about 2000 mg, including values and ranges thereof, per kilogram of body weight.

[0050] The total daily dose can be administered once or a plurality of times in a day. In some embodiments, the total daily dose is administered orally or parenterally.

[0051] For oral administration, picolinic acid or a salt or derivative thereof may be provided in the form of an oral dosage form containing 1, 2.5, 5, 10, 15, 20, 25, 30, 50, 75, 100, 125, 150, 200, 250, 300, 400 and 500 milligrams of picolinic acid or a salt or derivative thereof. Oral dosage forms containing picolinic acid or a salt or derivative thereof can be discrete units, such as hard or soft capsules, tablets, pills, or lozenges; or in a liquid form such as emulsions, solutions, suspensions, syrups, and elixirs.

[0052] For parenteral administration, e.g., intravenous administration, picolinic acid or a salt or derivative thereof may be administered in an amount of about 0.1 to 10 mg/kg/minute. For parenteral administration, a parenteral dose form containing desired amount of picolinic acid or a salt or derivative thereof may be formulated.

[0053] For intranasal administration, administration by inhalation, or administration by nebulization, picolinic acid or a salt or derivative thereof can be delivered in the form of a solution, suspension or aerosol.

[0054] In some embodiments, picolinic acid or a salt or derivative thereof may be provided in the form of a dietary supplement containing about 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, 100, 125, 150, 200, 250, 300, 400 and 500 milligrams of picolinic acid or a salt or derivative thereof. Said dietary supplement can contain one or more carriers suitable for oral ingestion. A dietary supplement composition can be in the form of a powder, liquid, solution, suspension, pill, capsule, tablet, gel cap, gel, nutrition bars, etc.

[0055] In some embodiments, the present disclosure provides use of picolinic acid or a salt or derivative thereof for inhibiting entry of a virus into a host cell. In some embodiments, the virus is SARS-CoV-2, influenza, parainfluenza, HSV, JEV, Zika virus, or a flavivirus and the host cell is a mammalian cell, an avian cell or a plant cell.

[0056] In some embodiments, the present disclosure provides picolinic acid or a salt or derivative thereof for use as a medicament for treating or preventing a viral infection in a subject. In some embodiments, the viral infection is a SARS-CoV-2, influenza, parainfluenza, HSV, JEV, Zika virus, or a flavivirus infection. Dosage forms, dosages, and routes of administration that may be employed for the medicament are discussed above.

[0057] In some embodiments, the present disclosure provides a method for treating a plant viral infection comprising applying to the plant or contacting the plant cell with picolinic acid or a salt or derivative thereof. In some embodiments, plant viruses that can be treated by application of picolinic acid or a salt or derivative thereof include, but are not limited to, viruses of family Geminiviridae (e.g., Cassava Mosaic Virus, Maize streak virus); Caulimoviridae (e.g., Banana streak virus, Rice Tungro Bacilliform virus); Potyviridae (e.g., Sugarcane mosaic virus, Maize dwarf mosaic virus, Sweet potato feathery mottle virus); Tombusviridae (e.g., Barley yellow dwarf viruses); Bromoviridae (e.g., Cucumber mosaic virus); and Nanoviridae (e.g., Banana bunchy top virus).

[0058] In some embodiments, the present disclosure provides a horticultural, arboricultural, or agricultural composition (collectively referred to herein as a “plant formulation”) where picolinic acid or a salt or derivative is formulated for application to plants for treating plant viral infections. In some embodiments, the plant formulation is a liquid formulation such as a solution or suspension that can be manually applied to plants or sprayed on plants. In some embodiments, the plant formulation is an aerosol formulation that is sprayed on plants. In some embodiments, the plant formulation is a dry formulation such as granules, powder, etc. that is

added to soil. In some embodiments, the plant formulation is a spray formulation that is a liquid or aerosol that can be sprayed on plants. The amount of picolinic acid or a salt or derivative thereof in the plant formulation can range from about 10% to about 95%, including values and ranges thereof, by weight of the formulation depending on the type of formulation and the place of application (leaves, stem, soil, etc).

[0059] In some embodiments, the amount of picolinic acid or a salt or derivative thereof in the plant formulation ranges from about 10-95%, 10-90%, 10-85%, 10-80%, 10-75%, 10-70%, 10-65%, 10-60%, 10-55%, 10-50%, 10-45%, 10-40%, 10-35%, 10-30%, 10-25%, 10-20%, 20-90%, 20-80%, 20-75%, 20-70%, 20-65%, 20-60%, 20-55%, 20-50%, 20-45%, 20-40%, 20-35%, 20-30%, 25-90%, 25-85%, 25-80%, 25-75%, 25-70%, 25-65%, 25-60%, 25-55%, 25-50%, 25-45%, 25-40%, 25-35%, 30-90%, 30-85%, 30-80%, 30-75%, 30-70%, 30-65%, 30-60%, 30-55%, 30-50%, 30-45%, 30-40%, 35-90%, 35-85%, 35-80%, 35-75%, 35-70%, 35-65%, 35-60%, 35-55%, 35-50%, 35-45%, 40-90%, 40-85%, 40-80%, 40-75%, 40-70%, 40-65%, 40-60%, 40-55%, 40-50%, 45-90%, 45-85%, 45-80%, 45-75%, 45-70%, 45-65%, 45-60%, 45-55%, 45-50%, 50-90%, 50-85%, 50-80%, 50-75%, 50-70%, 50-65%, 50-60%, 55-90%, 55-85%, 55-80%, 55-75%, 55-70%, 55-65%, 60-90%, 60-85%, 60-80%, 60-75%, 60-70%, 65-90%, 65-85%, 65-80%, 65-75%, 70-90%, 70-85%, 70-80%, 75-90%, 75-85%, or 80-90%, including values and ranges thereof, by weight of the formulation.

[0060] The plant formulations comprise one or more horticulturally or agriculturally suitable excipients. In some embodiments, the plant formulations comprise solvents such as water or a mixture of water with an organic solvent; surfactants; humectants, etc.

[0061] It is to be understood that the foregoing descriptive matter is illustrative of the disclosure and not a limitation. While considerable emphasis has been placed herein on the particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. Those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. Similarly, additional embodiments and features of the present disclosure will be apparent to one of ordinary skill in art based upon description provided herein.

[0062] Descriptions of well-known/conventional methods/steps and techniques are omitted so as to not unnecessarily obscure the embodiments herein. Further, the disclosure herein provides for examples illustrating the above-described embodiments, and in order to illustrate the embodiments of the present disclosure certain aspects have been employed. The examples used
5 herein for such illustration are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the following examples should not be construed as limiting the scope of the embodiments herein.

EXAMPLES

10 Example 1: Picolinic acid inhibits replication of human Parainfluenza, Herpes, and Influenza virus

[0063] Cytotoxicity of picolinic acid (PA) was tested by incubating human lung epithelial cells (A549 cells) with increasing concentrations of PA for up to 72 hrs and cell viability was measured at every 12 hr time intervals using Alamar Blue cell viability reagent (FIG. 1A).

15 A549 cells were procured from ATCC, Manassas, Virginia, USA.

[0064] Drug concentration up to 2mM PA was shown to be non-toxic to cells over the period of 72hr tested. The highest concentration of 20mM resulted in loss of cell viability 36hr post treatment. Based on these results, a working concentration of 2mM or below was used for all subsequent experiments.

20 [0065] A549 cells were pre-treated with 2mM PA for 3 hrs, washed and infected with firefly luciferase expressing Influenza virus (NS1 Luc), Para Influenza virus (HPIV Luc), and Herpes Simplex virus 1 (HSV1 Luc) either in the presence of PA. A second set of A549 cells was not pre-treated with PA (untreated) and was infected with the above-mentioned firefly luciferase viral constructs in the absence of PA. This set served as untreated virus control. Luminescence
25 assay was performed 48hr post infection, using Promega firefly luciferase assay system and results were plotted against percentage of untreated virus control (FIG. 1B). The cells pre-treated with 2mM PA showed 70-80% inhibition of the three different viruses tested.

[0066] VeroE6 cells (procured from ATCC, Manassas, Virginia, USA) were pre-treated with 2mM PA, washed, and infected with Japanese Encephalitis Virus (JEV) clinical strain P20778
30 in the presence of PA. A second set of VeroE6 cells was not pre-treated with PA (untreated)

and was infected with JEV P20778 in the absence of PA. This set served as untreated virus control. Cells were lysed 48hr post infection, cell lysates were prepared followed by the western blot analysis. Virus envelope protein expression levels were detected using anti-Flavivirus 4G2 antibody. A relative density of the bands was normalized against actin loading control and plotted using GraphPad Prism (FIG. 1C). A 0.75-fold decrease in the flavivirus envelope protein expression was evident from western blot analysis of JEV infected cells, treated with PA.

[0067] These results indicate a broad-spectrum activity of PA across both DNA (HSV) and RNA (influenza A virus, parainfluenza virus, and JEV) viruses belonging to three different families.

Example 2: Picolinic acid inhibits influenza A virus entry

[0068] In this experiment, cells were divided into four groups: (i) Untreated Control: cells were not treated with PA at any time during the experiment; (ii) Before Infection: cells were pre-treated with 2mM PA for 3 hr and infected with the virus in the presence of PA; (iii) During Infection: cells were infected with the virus in the presence of PA; and (iv) After Infection: cells were infected with the virus and 3 hrs later treated with PA. This is discussed in more details below.

[0069] A549 cells were pre-treated with 2mM PA for 3hr (Before Infection), washed and infected (T0) with PR8 WT virus (strain A/Puerto Rico/8/1934 H1N1) at 2 multiplicity of infection (MOI) in the presence of 2mM PA. After 3hr infection (T0+3hr), the cells were fixed with 4% formalin, permeabilized and used for immunofluorescence assay. See FIG. 2A, "Before Infection".

[0070] A mixture of 2MOI PR8 WT and 2mM PA was made in 1.5 tubes (During Infection), incubated at 37°C for 1hr and used to infect cells. Cells were fixed 3hr post infection and used for immunofluorescence assay. See FIG. 2A, "During Infection".

[0071] Cells were infected with 2MOI PR8 WT virus, 3hr later (After infection) treated with 2mM PA and fixed after a further incubation period of 6hr (To+9hr). See FIG. 2B.

[0072] Immunolabelling of virus infected cells was done using mouse anti-Influenza virus nucleoprotein (NP) antibody, followed by detection with Alexa Fluor 488 labelled anti-mouse secondary antibody.

5 [0073] Total number of NP positive cells was quantified using ImageJ/Fiji from 6 different microscopic fields per experimental condition. The results were plotted against percentage of untreated virus control using GraphPad Prism. See FIG. 2C.

[0074] Western Blot analysis was performed for lysates collected from different conditions as indicated, and virus protein expression was detected using mouse anti-Influenza virus NP antibody. See FIG. 2D.

10 [0075] A 75% decrease in number of NP positive cells compared to virus control was observed when cells were pre-treated with 2mm PA (Before Infection) and there was only a 40% decrease when cells were infected with virus and drug mixture (During Infection). A similar trend was observed in western blot analysis as well. However, no decrease in NP positive cells was observed when cells were treated 3hr post infection (After Infection). Similarly, no
15 difference was observed between expression levels of virus NP in virus control and PA treated cells by western blot.

[0076] Results from both immunofluorescence and western blot assays showed the anti-viral activity of PA when cells were pre-treated with PA. This indicates that PA interferes with the virus entry or early steps associated with the virus entry. PA did not show anti-viral activity
20 when cells were treated with PA after infection, implying that virus entry has already occurred during this time and that PA did not inhibit late events in virus replication. Although PA did not inhibit late events in virus replication, PA will inhibit entry of progeny virus, generated from virus replication, into host cells.

25 **Example 3: Picolinic Acid inhibits Influenza A Virus (IAV) induced disease in mice at a non-toxic dose**

[0077] Healthy 4-6 weeks old female BALB/c mice (procured from the Central Animal Facility at Indian Institute of Science, Bengaluru) were treated (N=5 per group) with 20 or 100 mg PA by intraperitoneal route. One group served as PBS (untreated) control. The body weight of animals was measured every day for up to 9 days post treatment and percentage differences in
30 body weight was plotted. See FIG. 3A. Drug toxicity results showed a gradual 10-12% decrease

in total body weight of animals treated with 100 mg PA. However, there were no differences in body weight of animals treated with 20 mg PA and this was similar to that of PBS treated control animals.

[0078] Test group of mice were treated with 20mg PA for 6hr and then infected with IAV PR8 WT strain via intra nasal route (N=5 per group). Control group of mice did not receive PA. Animals inoculated with PBS alone served as the non-infected control. The body weights of animals were then monitored over a period of 9 days and percentage differences in body weight was plotted using GraphPad Prism. See FIG. 3B. Animals infected with PR WT in the presence of 20 mg PA showed minimal loss in body weight followed by a recovery phase after 8 days infection. This was in contrast to the 30% body weight loss that was observed in the case of animals infected in the presence of 100 mg PA.

[0079] A working concentration of 20mg PA was chosen based on the toxicity study and this concentration was shown to rescue animals from PR8 WT virus infection, as evidenced by reduced body weight loss in the presence of the drug. The results correlate with *in vitro* data performed in A549 cells shown in FIG. 1A, wherein nontoxic dose of PA was shown to inhibit virus replication.

Example 4: Picolinic Acid inhibits IAV replication and pathology in mice at a non-toxic dose

[0080] Healthy 4-6 weeks old female BALB/c mice (procured from the Central Animal Facility at Indian Institute of Science, Bengaluru) were treated with 20mg PA for 6hr and then infected with IAV PR8 WT strain via intra nasal route (N=5 per group). Control group of mice did not receive any PA. Animals inoculated with PBS alone served as the noninfected control. The survival rate of animals was then monitored for up to 9 days and plotted. See FIG. 4A. Beginning at 3 days post infection, a steady decrease in survival rate of control animals without PA treatment was observed, resulting in over 80% decrease in percentage survival after 9 days. This effect was significantly reduced in animals treated with 20mg PA.

[0081] Mice from both control and drug treated groups were sacrificed 72hr post infection and total lung tissue was recovered and homogenized. Virus titre from the tissue homogenate was then measured using influenza virus plaque assay in MDCK cells and results plotted using GraphPad Prism. See FIG. 4B. Over 10-fold decrease in virus titre from lung tissue samples was evident in infected animals treated with PA compared to untreated.

[0082] The rescue of PA treated animals from IAV induced death correlates well with the previously observed results of reduced body weight loss. Reduction of lung virus titre in PA treated animals is a clear indication of antiviral effects *in vivo*.

Example 5: Picolinic Acid inhibits SARS-CoV-2 entry in Pseudotyped particle assay

5 [0083] FIG. 5A shows a schematic illustrating different steps involved in the production of pseudotyped SARS CoV-2 particles. This schematic is sourced from *Viruses* 2020, 12(5), 513; www.doi.org/10.3390/v12050513. 293T cells were transfected with plasmids encoding a lentiviral backbone (genome) expressing a marker protein, SARS CoV-2 spike, and other HIV proteins needed for virion formation (Tat, Gag-Pol, and Rev). After 60hr, the pseudotyped
10 particles were collected and used for infection of cells expressing ACE2 receptor.

[0084] HEK ACE2 cells (procured from BEI Resources, Manassas, Virginia, USA) in a 96 well plate were pre-treated for 3hr with 2mM PA, 10µM Chloroquine (CQ) or 500µM Camostat mesylate (CM) individually, washed and infected with pseudotyped SARS CoV-2 particles in the presence or absence of respective drugs. Firefly (Luc2) luminescence readings were
15 measured 72hr post infection and results were plotted against percentage of untreated virus control using GraphPad prism. See FIG. 5B. Over 50% inhibition of pseudotyped SARS CoV-2 virus entry was observed in the presence of 2mM PA, compared to 60 and 90% inhibition that was observed with CM and CQ, respectively.

[0085] The results indicate that PA treatment of cells inhibited pseudotyped SARS CoV-2 virus
20 entry at an IC₅₀ of 2mM and this was almost 10% more effective than CM, an inhibitor of the cellular enzyme transmembrane protease serine 2 (TMPRSS2).

Example 6: Picolinic Acid inhibits SARS-CoV-2 replication in different cell lines

[0086] VeroE6 (procured from ATCC, Manassas, Virginia, USA), HEK ACE2 (procured from BEI Resources, Manassas, Virginia, USA) and Calu3 cells (procured from ATCC, Manassas,
25 Virginia, USA) were seeded in 24 well cell culture plates. The cells were pre-treated for 3hr with 2mM PA, washed and infected with 0.01 MOI SARS-CoV-2 (isolate hCoV-19/Hong Kong/VM20001061/2020 procured from BEI Resources, Manassas, Virginia, USA) in the presence of PA. A control set of cells for each cell line was not pre-treated with PA and was infected with the SARS-CoV-2 virus strain in the absence of PA. After 48hr infection, the cells

were washed, and total RNA was isolated using Trizol. Viral RNA load was determined by RT-qPCR and results were plotted against log₁₀ copy number of viral RNA.

[0087] A three log₁₀ decrease in total viral RNA copy numbers was observed in both VeroE6 and HEK ACE2 cells treated with 2mM PA, compared to almost 1 log₁₀ decrease seen in Calu3 cells. See FIG. 6.

[0088] These results indicate that PA exhibits potent antiviral activity against SARS-CoV-2 in cells lines of different species.

Example 7: Picolinic acid inhibits SARS-CoV-2 and a range of other viruses

[0089] In this experiment, the *in vitro* antiviral efficacy of PA against SARS-CoV-2 was tested using cells lines from both human and non-human primate origin. To this end, HEK ACE2 cells were pre-treated for 3hr with increasing doses of PA as indicated, infected with 0.1 MOI of either SARS-CoV-2 Hong Kong (FIG. 7, panel A) or four SARS-CoV-2 variants of concern (FIG. 7, panel B). Cells were collected 48hr p.i, viral RNA copy estimated by qRT PCR and corresponding cell viability of uninfected drug treated cells were plotted. VeroE6 cells were infected with 0.001 MOI for all viruses as mentioned above (FIG. 7, panels C and 7D). Results showed a 4-log₅ reduction in viral RNA load upon treatment with non-toxic (2mM) concentrations of PA (FIG. 7, panels A and C). In a similar experimental setup using Calu3 cells, 2mM PA treatment resulted in a 2-log reduction in viral load (FIG. 7, panel E). Varying levels of inhibition were seen upon testing PA on SARS-CoV-2 variants of concern, best results being observed against alpha variant in HEK ACE2 cells, as evidenced by a 5-log reduction viral RNA load. A 2.5 log reduction in gamma variant, and ~1 log reduction was seen in the case of beta and delta variants (FIG. 7, panel B). Infection of VeroE6 cells resulted in comparatively higher viral loads in the untreated controls, which was in turn significantly abrogated by ~1 log for all 4 variants tested (FIG. 7, panel D).

[0090] To further investigate the broad-spectrum activity of PA, its effects against a panel of viruses including Influenza A viruses (IAVs) in MDCK cells were tested. MDCK cells pre-treated with increasing concentrations of PA were infected with 0.01MOI of PR8 wild type virus and 48hr p.i, virus from supernatants were quantified by plaque assay (FIG. 7, panel F). In the case of PR8 wild type virus, a dose dependent decrease in infectious virus was observed at 48hr post infection (p.i), with maximum (50%) inhibition seen in the presence of 2mM PA (FIG. 7, panel F). A549 cells pre-treated with 2mM PA were infected with different luciferase

reporter viruses as indicated. Cells were harvested 48hr p.i for luciferase assay and data normalized with untreated control are shown (FIG. 7, panels G and J). A 3-fold reduction in X79 virus titer was seen at this concentration, compared to Cal/09 and HALo strains. Multi-cycle infection in A549 cells infected with DENV and Zika reporter viruses showed >90% inhibition in the presence of 2mM PA (FIG. 7, panels G and H). The anti-flavivirus effects of PA was supported by inhibition of Japanese encephalitis Virus (JEV) clinical strain P20778, and wild type Zika virus (ZIKV) Cambodia strain as shown by western blot analysis of Flavivirus envelope protein (FIG. 7, panels K and L). Human parainfluenza virus (HPIV) and herpes simplex virus (HSV) reporter virus assays showed 80-90% inhibition at this drug concentration (FIG. 7, panels I and J).

Example 8: Picolinic acid inhibits SARS-CoV-2 in a preclinical animal model

[0091] To understand whether PA shows antiviral effects against SARS-CoV-2 *in vivo*, *in vivo* studies were performed in Syrian golden hamsters. PA toxicity studies in BALB/c mice using 20 and 100 mg/kg body weight of drug revealed the latter to be toxic when administered via oral route (FIG. 9, panels B and C). Based on this, 20mg/kg PA was used for all treatment regimens via both IP and oral routes in mice and hamsters. Prophylactic and therapeutic dosage regimens in hamsters are shown in FIG. 8, panels A and B respectively. Prophylactic treatment of hamsters involved administration of PA at 1, 2 and 3 days prior to infection, followed by virus challenge at day 0. Therapeutic treatment used dosage during 1, 2 and 3 dpi (days post-infection). Viral RNA copy number from lung tissue homogenates for both prophylactic and therapeutic treatment groups is shown in FIG. 8, panel C and corresponding total lung weight loss percentage up to 4 dpi is shown in FIG. 8, panel D. Administration of 20mg/kg PA prophylactically by IP injection caused a ~2.5-fold reduction in lung viral load, compared to a 1 log decrease when the drug was delivered orally. Therapeutic treatment by both routes mitigated viral RNA load by ~1 log. These observations were consistent with both body weight as well as corresponding lung weight rescue, compared to mock treated animals (FIG. 8, panels D-F). FIG. 8, panel E shows a percentage bodyweight loss in the prophylactic group and FIG. 8, panel F shows a percentage bodyweight loss in the therapeutic treatment group. Upon dosage of CQ therapeutically, lung viral loads were reduced by ~1 log, compared to that of PA administered via the same route (FIG. 8, panel C). Images of whole lungs harvested from sacrificed animals manifested gross pathology and inflammation in mock treated, compared to the healthy control, with much of the pathology reduced in lungs from PA treated groups (FIG.

8, panel G). FIG. 8, panel H shows histology images of lung tissue sections for all treatment groups including mock infected and healthy controls. Scoring of histology sections was done based on following criteria (1) alveolar edema, (2) vascular and perivascular infiltration (3) alveolar thickening and infiltration. Scoring was done based on severity on a scale of 1-4 (1-mild, 2-moderate, 3-severe, 4-very severe). An overall score was given by accumulating the total scores for each criterion, results are shown in (I). Evidence from histopathology analysis and scoring clearly showed decreased pathology (FIG. 8, panels G and H).

Example 9: Picolinic acid inhibits Influenza A virus in mice model

[0092] In view of the broad-spectrum activity of PA across multiple cell lines, and efficacy versus SARS CoV-2 inferred from the above studies in hamsters, the effect of PA in mitigating other viruses was studied *in vivo* in a mouse model. FIG. 9, panel A shows schematics showing toxicity and infection/treatment schedule for Influenza A virus (IAV) infection in BALB/c mice. Toxicity studies in BALB/c mice used administration of PA via oral or IP routes and monitoring of bodyweight up to day 9 post treatment. Toxicity results with bodyweight changes over 9 days post treatment with 20mg/kg PA and 100 mg/kg PA delivered via IP and oral routes are shown in FIG. 9, panels B and C respectively. Based on these studies, 20 mg/kg PA dose was selected.

[0093] Prophylactic and therapeutic treatment used administration of PA 6hr prior and 3hr post infection respectively, survival was monitored up to day 4 p.i and bodyweight loss for remaining animals till day 7. FIG. 9, panel D shows a plaque assay quantification of infectious virus titer from lungs tissue homogenates. The plaque assay quantification showed >10-fold reduction in mice treated prophylactically with 20mg/kg PA via oral and IP routes. Therapeutic treatment was more effective in abrogating lung virus titers when the drug was administered via IP route (FIG. 9, panel D). FIG. 9, panels E and F show a percentage survival and body weight loss up to day 7 post infection, respectively. The treatment of mice with PA was shown to completely rescue animal survival in all the groups tested, except for IP prophylactic (80% survival), over the course of 7 days p.i (FIG. 9, panel E). Over 90% rescue of total animal body weight was seen for all groups. Mice bodyweight from IP prophylactic group declined from day 2, but still showed >10% rescue compared to virus control at day 7 (FIG. 9, panel F). FIG. 9, panel G shows histology images of mice lung specimens for all treatment groups including mock infected and healthy controls. Histology analysis showed marked reduction in pathology, with best rescue observed in therapeutic oral group. Histology sections were scored based on

the following clinical criteria, namely (1) vascular infiltration, (2) alveolar infiltration and (3) interstitial pneumonia. Scoring was done based on severity on a scale of 1-4 (1-mild, 2-moderate, 3-severe, 4-very severe). An overall score was given by accumulating the total scores for each criterion, the results are shown in FIG. 9, panel H. All treated groups showed recovery, as evidenced by the clinical scores shown in FIG. 9, panel H.

Example 10: Time of addition studies reveal inhibition of virus entry as mechanism of action for picolinic acid antiviral activity

[0094] To identify the mechanism of action (MoA) of PA on viruses, time of addition assays were employed wherein cells were treated with PA at different time points before and after infection. Specifically, cells were either pre-treated for 3hr with 2mM PA, infected with 10 MOI SARS-CoV-2 in presence of PA and collected 3hr later (-3hr); or treated during infection (T0); or PA was added 6hr p.i and collected a further 3hr later (T0+6hr); or virus and PA were incubated together for 1hr and used for infection (1hr virus+PA). SARS-CoV-2 infection of pre-treated HEK ACE2 (FIG. 10, panels A-C) and VeroE6 (FIG. 10, panels D-F) cells with 2mM PA for 3hr mitigated virus replication by >80% as shown by IFA images and quantification of cells positive for virus spike protein associated immunofluorescence (FIG. 10, panel A and panel B, left graph). Similar effects were also seen when virus and drug were incubated for 1hr before infection. However, when cells without pre-treatment with PA were infected in the presence of drug (T0), almost no inhibition was observed in either cell line (FIG. 10, panel A, panel B-left graph, panel D, and panel E-left graph). These findings were supported by western blot data for virus spike protein (FIG. 10, panels C and F). To test effects of PA on post-entry stages of virus replication cycle, drug was added 6hr post infection and collected 3hr later. Here, ~50% inhibition of virus was observed in HEK ACE2 cells and no inhibition was found in VeroE6 cells, as seen by IFA images (FIG. 10, panel A, panel B-right graph, panel D, and panel E-right graph) and western blot analysis (FIG. 10, panels C and F-right graphs).

[0095] HEK ACE2 cells pre-treated with 2mM PA were infected with SARS-CoV-2 spike pseudotyped particles in the presence of PA and harvested 60hr later. Results show firefly luciferase values normalized to virus control. Infection of HEK ACE2 cells using SARS-CoV-2 spike pseudotyped particles in the presence of increasing PA concentrations revealed a dose-dependent effect, with 90% inhibition at 2mM concentration (FIG. 10, panel G).

[0096] Entry effects of PA against PR8 WT virus were tested in A549 cells. Specifically, A549 cells were either pre-treated for 3hr with 2mM PA, infected with 2 MOI PR8 WT in presence of drug and collected 3hr later (-3hr); virus was incubated with 2mM PA for 1hr and used for infection (1hr virus + PA); or PA was added 6hr p.i and collected a further 3hr later (T0+6hr). IFA results showed 80% inhibition upon 3hr pre and post treatment with PA (FIG. 10, panels H and I). As in the case of SARS-CoV-2, when virus was incubated with drug, and subsequently used for infection, a 50% inhibition was seen, as observed by IFA for virus nucleoprotein and western blot (FIG. 10, panels H and I). No differences were observed when PA was added 6hr post infection (FIG. 10, panels H and I). The findings from IFA were also reflected in western blot analysis of the same samples (FIG. 10, panel J).

Example 11: Picolinic acid inhibits virus-membrane fusion, disrupts viral envelope

[0097] To understand the precise mechanism of action mediating inhibition of virus entry, the effects of PA on virus spike mediated syncytia formation were studied using SARS-CoV-2. VeroE6 cells transfected with a plasmid expressing SARS-CoV-2 spike protein were treated with increasing concentrations of PA, and 24hr later, fixed and labelled with wheat germ hemagglutinin (WGA) and DAPI. Area of syncytia was quantified using ImageJ/Fiji and plotted as percentage of untreated control (FIG. 11, panel A). Results showed a dose-dependent inhibition of virus spike induced syncytia formation. 1 and 2mM PA treatment resulted in 70 and 80% inhibition of syncytia respectively, as shown by IFA images and quantification of syncytia from respective treatment conditions (FIG. 11, panel A).

[0098] Next, the effects of PA in inhibiting influenza virus-endosome fusion were tested. A549 cells were pre-treated with either 2mM PA, 10 μ M NH₄Cl or 10 μ M CQ, infected with R18 labelled PR8 WT virus on ice, transferred to a plate reader at 37°C and the increasing fluorescence signal associated with virus-endosome fusion during virus entry was quantified over a period of 90 min at 10 min intervals. Results shown in FIG. 11, panel B show that cells treated with 2mM PA or control drugs 10 μ M ammonium chloride (NH₄Cl) and 10 μ M Chloroquine diphosphate (CQ) were all able to inhibit virus-entry associated increase in fluorescence intensity.

[0099] Next, fluorescent transferrin conjugates (Tf 647) were used to test the possible effects of PA on clathrin mediated endocytosis. A549 cells pre-treated with 2mM PA were pulsed with 25 μ g/mL Tf647 for 1hr in the presence of PA, washed and analyzed by flow cytometry to

quantify the percentage of Tf647 positive cells. 1hr pulse of A549 cells with Tf647 in the presence of 2mM PA did not show any differences in cellular uptake of transferrin (FIG. 11, panel C). Further, the intracellular localization of Tf647 labelled endocytic vesicles in PR8 WT virus infected VeroE6 cells treated with 2mM PA was studied. PA treated VeroE6 cells were incubated with Tf647 and 100MOI PR8 WT virus for 1hr on ice and moved to 37°C. After 1hr, cells were washed and incubated for 15 min at 37°C before fixation with 4% formalin. Images were acquired using a confocal microscope and distance of Tf647 labelled vesicles from nuclei was quantified using Imagej/Fiji. A characteristic scattering of Tf647 loaded endocytic vesicles and influenza virus NP labelled PR8 WT virus particles in drug treated cells was observed (FIG. 11, panel D). Quantification of Tf647 associated fluorescence intensity showed endocytic vesicles in PA treated cells to be localized up to 15-20 microns away from the nuclei (FIG. 11, panel E).

[00100] Furthermore, Transmission electron microscopy (TEM) imaging of PA treated PR8 WT virus particles was employed to study whether the virus entry targeting effects of PA is due to disruption of virion structural integrity. For this, PR8 WT virus particles were incubated with either 2mM PA, 0.01% Triton X100 or distilled water for 3hr, mounted on copper grids and stained with uranyl acetate for TEM imaging. Results showed severe disruption of viral envelope compared to untreated control. The positive control using 0.01% Triton X 100 treated virus particles also showed similar effects on these viruses (FIG. 11, panel F).

Example 12: Picolinic acid exhibits limited antiviral activity against naked viruses, does not affect bacteriophages

[00101] The effects of PA against non-enveloped viruses were tested to see if PA would be effective against non-enveloped viruses as well. To this end, HeLa cells were either pre-treated for 3hr with 2mM PA, infected with 10 MOI Coxsackie virus B3 in presence of PA and collected 3hr later (-3hr); or treated during infection (T0); or virus and PA were incubated together for 1hr and used for infection (1hr virus+PA). FIG. 12, panel A shows quantification of virus infection by western blot using VP1 antibody. The data showed that pre-treatment of cells, incubation of virus with drug prior to infection, and treatment at the time of infection, did not have any effects on virus entry, as seen by western blot data for virus VP1 protein (FIG. 12, panel A).

[00102] Further, Vero cells were pre-treated with increasing concentrations of PA as indicated and infected with 0.1 MOI CVB3 in the presence of drugs. 48hr p.i, cell culture supernatants were used to quantify infectious virus by plaque assay. Infectious virus from cell culture supernatants was quantified by plaque assay and results did not imply any differences across the multiple PA doses tested (FIG. 12, panel B).

[00103] Next, HEK cells pre-treated with 2mM PA were infected with Rota virus RRV strain, fixed with 4% formalin after 12hr and immunolabelled with VP6 antibody and DAPI to label the virus particles and nuclei respectively. Percentage positive cells was quantified using ImageJ/Fiji. The data showed that pre-treatment of cells did not have any effects on virus entry as shown by IFA images and quantification of VP6 positive cells (FIG. 12, panel C).

[00104] HEK cells pre-treated with 2mM PA were infected with AAV6-GFP particles in presence of drug at different volumes as indicated. 48hr p.i, cells were harvested and analyzed for GFP positive cells by flow cytometry. HEK cells infected with increasing volumes of the AAV6-eGFP preparations in the presence of 2mM PA, resulted in 5-10% decrease in GFP positive cells in all conditions tested (FIG. 12, panel D). In a similar experimental setup, HEK cells pre-treated with 2mM PA were infected with 10MOI Adenovirus 5 expressing eGFP in the presence of drug and harvested 24hr later for quantification of GFP positive cells by flow cytometry. Almost no differences were observed between GFP positive HEK cells in treated and untreated conditions (FIG. 12, panel E).

[00105] Since most of the naked viruses tested were not inhibited by PA, whether PA would be effective against TM4 mycobacteriophages. *M. smegmatis* cells in a 48 well plate were treated with increasing concentrations of PA as indicated and OD600 measurements were taken periodically up to 24hr. The data showed the least concentration of 1mM PA to be non-toxic (FIG. 12, panel F). For the antiviral assay, 1mM PA was either added at the start of experiment or 3 hr prior to infection. In either case, there was no protection from TM4 mycobacteriophage induced cell death (FIG. 12, panel G).

Example 13: Methods Detail for Examples 7-12

Ethics Statement

[00106] The study designs were reviewed and approved by institutional biosafety committee guidelines, (IBSC/IISc/ST/17/2020), following the Indian Council of Medical Research and Department of Biotechnology recommendations. All experiments involving animals were

reviewed and approved by the Institutional Animal Ethics Committee (Ref: IAEC/IISc/ST/784/2020) at the Indian Institute of Science and conducted in a Viral Biosafety level-3 facility. The experiments were performed according to CPCSEA (The Committee for the Purpose of Control and Supervision of Experiments on Animals) guidelines.

5 Cells and plasmids

[00107] The following cell lines were used in this study: HEK 293T cells expressing human ACE2 (NR-52511, BEI Resources, NIAID, NIH); HEK 293T, VeroE6 (CRL-1586, ATCC®); Madin-Darby Canine Kidney (MDCK); A549 Human Lung Carcinoma (NR-52268, BEI Resources, NIAID, NIH), Calu-3 (ATCC HTB-55) and BHK-21. All cell lines were cultured in complete Dulbecco's modified Eagle medium (12100-038, Gibco) with 10% HI-FBS (16140-071, Gibco), 100 IU/ml Penicillin and 100 µg/ml Streptomycin (15140122, Gibco) supplemented with GlutaMAX™ (35050-061, Gibco).

Viruses

[00108] The following SARS-CoV2 isolates were procured from BEI Resources, NIAID, NIH: Isolate Hong Kong/VM20001061/2020, NR-52282; Isolate hCoV-19/England/204820464/2020 (Lineage B.1.1.7 - Alpha variant), NR-54000; Isolate hCoV-19/USA/MD-HP01542/2021 (Lineage B.1.351 South Africa - Beta variant), NR-55282; Isolate hCoV-19/USA/PHC658/2021 (Lineage B.1.617.2; Delta Variant), NR-55611; Isolate hCoV-19/Japan/TY7-503/2021 (Brazil P.1 Gamma variant), NR-54982. All these viruses were propagated and titrated by plaque assay in Vero E6 cells as described before (Case et al., 2020). The following Influenza A virus (IAV) strains namely A/Puerto Rico/8/1934 (PR8), A/California/04/2009 H1N1 (Cal/09), Viet Nam/1203/04 H5N1 (HALo), and A/reassortant/X-79(Philippines/2/1982 x Puerto Rico/8/1934) (X79) were propagated in 11-day old embryonated chicken eggs and titrated by plaque assay in MDCK cells (Gaush and Smith, 1968).

[00109] Japanese Encephalitis Virus (JEV) clinical strain P20778 was propagated and titrated in BHK-21 cells. The reporter viruses used in this study include IAV expressing Gaussia luciferase (NS1 Luc) (Eckert et al., 2014); Dengue virus (DENV Luc), Zika Luc, Human parainfluenza virus (HPIV Luc) and Herpes Simplex Virus (HSV Luc) expressing renilla luciferase.

[00110] Adenovirus Serotype 5, Clone Ad5-CMV-hACE2/RSV-eGFP, Recombinant Expressing Human ACE2 was procured from BEI resources (Catalog No. NR-52390).

[00111] Coxsackie virus B3 was a kind gift from Prof. Saumitra Das, Department of Microbiology and Cell Biology, Indian Institute of Science, Karnataka.

[00112] Rota virus RRV strain was a kind gift from Prof. Durga Rao.C, SRM University, Andhra Pradesh.

- 5 [00113] TM4 mycobacteriophage (Bajpai et al., 2018) was amplified in *M. smegmatis* and phage enumeration was done using the soft agar overlay technique as reported by Kalapala et al (Kalapala et al., 2020).

SARS CoV-2 multi-cycle experiments

- 10 [00114] HEK ACE2 or Vero E6 cells were seeded in 24-well cell culture plates to reach 70-80% confluency next day. Cells were pre-treated with 0.25, 0.5, 1 and 2mM PA for 3hr and infected with 0.1 MOI or 0.001 MOI SARS-CoV-2 Hong Kong strain in HEK ACE2 and Vero E6 cells respectively in the presence of drug. For infection, cells were first incubated with 100µL per well of inoculum and after 1hr adsorption, topped up with 400µL medium. DMEM
15 containing 2% FBS was used for infection in Vero E6 cells and complete DMEM was used for HEK ACE2 cells. After 48hr, total RNA from infected cells was extracted using Trizol and viral copy number was estimated by qRT PCR. Cell viability of uninfected, drug treated cells was measured using Alamar blue cytotoxicity assay (DAL 1025, Invitrogen) as per manufacturer's instructions.

- 20 [00115] Similarly, the effect of PA against SARS-CoV-2 variants of concern was tested by first pre-treating HEK ACE2 and VeroE6 cells with 2mM PA. Four different variants of concern namely Alpha, Beta, Gamma or Delta were used to infect HEK ACE2 (0.1 MOI) and Vero E6 (0.001 MOI) cells as mentioned above. After 48hr infection, total viral RNA copy number from infected cells was estimated by qRT PCR. VeroE6, Calu3 and HEK ACE2 cells
25 were seeded in 24-well cell culture dishes to reach 80% confluency post 24hr. Cells were then pre-treated with 2mM PA in triplicates for 3hr and infected with 100µL per well 0.1 MOI SARS CoV-2 Hong Kong strain diluted in complete DMEM in the presence of drug. After 1hr adsorption, media in wells were topped up with 400µL DMEM containing 2mM PA. Viral copy number from infected cells was estimated by qRT PCR 48hr post infection.

30 Quantification of SARS-CoV-2 viral load by qRT PCR

[00116] Cells were harvested in TRIzol (15596018, Thermo Fisher) as per manufacturer's instruction. Equal amount of RNA was used to determine viral load using AgPath-ID™ One-Step RT-PCR kit (AM1005, Applied Biosystems). The following primers and probes targeting

the SARS CoV-2 N-1 gene were used for amplification. Forward primer: 5'GACCCCAAATCAGCGAAAT3' and Reverse primer: 5' TCTGGTTACTGCCAGTTGAATCTG3', Probe: (6-FAM / BHQ-1) ACCCCGCATTACGTTTGGTGGACC). The Ct values were used to determine viral copy number by generating a standard curve using SARS CoV-2 genomic RNA standard.

Multicycle IAV infection

[00117] MDCK cells were seeded in 24-well cell culture dishes to reach 80-90% confluency after 24hr. Cells were treated with 0.2, 0.5, 1, and 2mM PA for 3hr, washed once with warm PBS and infected with 0.01 MOI of PR8, HALo, Cal/09 and X79 viruses in OptiMEM reduced serum media (31985088, Gibco) containing 1µg/mL L-tosylamide-2-phenyl ethyl chloromethyl ketone (TPCK trypsin) (T1426, Sigma). The drug (2mM PA) was present throughout the duration of experiment. After 48hr, supernatants from wells were collected, centrifuged at 2.5xg to remove cell debris, and used for plaque assay.

IAV plaque assay

[00118] MDCK cells were seeded in 12-well plates to reach complete confluency after 24hr. 10-fold dilutions of supernatants collected from the multicycle experiment were prepared in OptiMEM and 100µL per well was used to infect cells for 1hr at 37 °C with regular shaking every 10 min. Virus inoculum was then removed and cells were overlaid with 1mL MEM containing 0.6% oxoid agar (LP0028, Thermo Scientific) and 1µg/mL TPCK trypsin. After 48hr, cells were fixed with 4% formalin and plaques visualized by crystal violet staining.

Reporter virus infection Assay

[00119] A549 cells at 80-90% confluency in a 24-well dish were treated with 2mM PA for 3hr in triplicates. Cells were then washed and infected with 1µL per well of Dengue Luc or Zika Luc; 0.2µL per well HPIV Luc or 1µL per well HSV Luc. 2mM PA was present/not in the medium throughout the duration of experiment. After 48hr, the cells harvested for detection of firefly and renilla luciferase expression using Dual-Luciferase Reporter Assay System (E1980, Promega) as per manufacturer's instructions. Luminescence measurements were taken using a TECAN Infinite 200-PRO multiplex reader.

Influenza virus infection studies in mice model and histopathology

[00120] Healthy 4-6 weeks old female BALB/c mice (Biogen Laboratory Animal Facility, Bengaluru, India) in groups of 4 were housed in individually ventilated cages (IVC) maintained

at 23±1°C temperature and 50±5% relative humidity. Animals were given access to standard pellet feed and water ad libitum and maintained on a 12-hour day/night light cycle at the Viral Biosafety level-3 facility, Indian Institute of Science. Animals were treated with 20 or 100 mg/kg PA by either intraperitoneal (IP) or oral routes. One group served as PBS (untreated) control. The body weight and general health of animals was measured every day for up to 9 days post treatment. Treatment groups were divided into two, one groups receiving 20mg/kg PA prophylactically and the other, therapeutically. For infection, mice under intraperitoneal (IP) Ketamine (90 mg/kg) (Bharat Parenterals Limited) and Xylazine (4.5 mg/kg) (21, Indian Immunologicals Ltd) anesthesia were challenged intranasally with 50 PFU of PR8 WT virus in 40µL PBS. Two dosage regimens and routes of drug administration were followed for the treatment of animals. Prophylactic treatment used administration of 20mg/kg/day PA via oral or IP route during 6hr before infection and therapeutic dosage (oral/IP) involved administering the same amount of drug 3hr post infection. One half of the animals were sacrificed at 4 dpi and lungs collected for plaque assay quantification of IAV and histology analysis. For remaining animals, total bodyweight and survival was recorded until end of the experiment at 7 dpi. For plaque assay, lung samples were collected in DMEM containing 0.3% BSA, homogenized and centrifuged at 5000xg for 10 min at 4°C to pellet tissue debris. The supernatant was used for plaque assay as mentioned previously. Lung samples were collected in 10% buffered formalin for histology analysis, processed and tissue sections of 4-6µm thickness made using a microtome. The sections were then stained with Hematoxylin and Eosin and examined by light microscopy as previously described (Chan et al., 2020). Three different clinical criteria were observed, namely: vascular infiltration, alveolar infiltration, and interstitial pneumonia. Scoring was done based on severity on a scale of 1-4 (1-mild, 2-moderate, 3-severe, 4-very severe).

Pseudotyped SARS CoV-2 particle production and transduction

[00121] Pseudotyped particles bearing the SARS-CoV-2 spike protein were produced as reported before (Crawford et al., 2020). Briefly, HEK 293T cells were seeded in 10 cm cell culture dishes to reach 50-60% confluency post 24hr and transfected with 2.5µg each of the following plasmids HDM-IDTSpike-fix (BEI, NR-52514); pHAGE-CMV-Luc2-IRES-ZsGreen-W (BEI, NR-52516); HDM-Hgpm2 (BEI, NR-52517); HDM-tat1b (BEI, NR-52518) and PRC-CMV-Rev1b (NR-52519) using Lipofectamine-2000 transfection agent (Invitrogen, 11668019). The supernatants were pooled together 60hr post-transfection, centrifuged at 18xg

for 10 min at 4°C to remove cell debris, and finally passed through a 0.45µm syringe filter before being used for transduction.

[00122] HEK ACE2 and Calu3 cells were seeded in 96-well dishes to reach 60-70% confluency after 24hr. Cells were treated with 2, 1, 0.5, and 0.2mM PA and 3hr later, transduced with 100µL per well pseudotyped SARS CoV-2 particles containing 5µg/mL polybrene (Merck, TR-1003-G). The different concentrations of PA were present throughout the experiment. Post transduction (60hr), cells were washed once with PBS and processed for detecting luciferase expression using a Firefly luciferase assay kit (Promega, E4550) as per the manufacturer's instructions. Luminescence measurements were taken using a TECAN Infinite 200-PRO multiplex reader.

Adeno Associated Virus - 6 production and infection

[00123] AAV6 production: AAV6 particles were produced as per a previously published protocol (Negrini et al., 2020) with few modifications. Briefly, HEK 293T cells were seeded in 2 X T75 flasks to reach 50-60% confluency the next day. For each flask, the following plasmids were transfected using Lipofectamine 2000 as per manufactures instructions: 17.7 µg pAdDeltaF6 (Addgene 112867), 7.9 µg pRepCap6 (Addgene 110770) and 5.9 µg pAAV-CAG-GFP (Addgene 37825). After 60hr, the cells and medium mixture were pooled and transferred to a 50mL conical tube. 3mL Chloroform was added, vortexed gently for 5 min and 8mL 5M NaCl was added. The tube was then centrifuged for 5 min at 3000 × g, 4°C and aqueous phase transferred to a fresh tube. 10mL of 50% (v/v) PEG 8000 was added, vortexed briefly and incubated for 1hr on ice before centrifuging for 30 min at 3000 × g, 4°C. The supernatant was then discarded, pellet re-suspended in 1.5mL HEPES, vortexed for 2 min and following components added: 3.5µL of 1M MgCl₂; 14µL DNase I (NEB, M0303S) and 1.4µL of 10µg/µL RNase A (Thermo, EN0531). The contents were incubated for 20 min at 37°C, equal volume to chloroform added to the tube and mixed well before centrifuging for 5 min at 3000 × g. Aqueous phase was then transferred to a new tube, followed by which the contents were passed through a 100kDa Amicon Ultra Centrifugal Filter (Merck-Millipore, UFC510008) by centrifugation for 5 min at 14,000 × g. The column was washed twice with PBS and AAV particles eluted into a fresh tube by centrifugation at 1000 × g for 2 min.

[00124] Infection with AAV6 particles: HEK 293T cells were seeded in a poly-L-lysine coated 24-well dish to reach 60-70% confluency the next day. Cells were pre-treated or not with 2mM PA for 3hr and infected with 100uL complete DMEM per well containing three different

volumes i.e 2, 5 and 10µl AAV6 particles. After 1hr, medium was topped up with 400µl complete DMEM. PA was present in the medium for entire duration of the experiment. After 48hr, cells were trypsinized and re-suspended in PBS containing 3% FBS (FACS buffer). The number of GFP positive cells was analyzed using a Cytoflex (Beckman Coulter) flow cytometer and results analyzed using CytExpert software.

Adenovirus 5 infection

[00125] For infection studies, HEK cells were pre-treated for 3hr with 2mM PA and infected with 10 MOI AAV5-eGFP in the presence of drug. After 24hr, cells were trypsinized, re-suspended in FACS buffer and used to quantify total number of GFP positive cells by flow cytometry analysis. Drug was present in the treated conditions throughout the duration of experiment.

Flavivirus infection

[00126] Confluent A549 cells in 24-well cell culture plate were pre-treated for 3hr with 2mM PA and infected with 100µL per well DMEM containing 0.1MOI JEV clinical strain P20778 or ZIKV Cambodia. After 1hr adsorption, the wells were topped up with 400µL DMEM. Drug (2mM PA) was present in the media throughout the duration of experiment. Cells were then washed with PBS and harvested for western blot analysis 48hr post infection. The separated proteins were transferred onto PVDF membrane and probed using mouse anti Flavivirus envelope 4G2 primary antibody and anti-mouse-HRP conjugated secondary antibody. Actin labelling using Mouse mAb to beta Actin-HRP (Abcam, ab49900) was used as loading control.

SARS-CoV-2 spike induced syncytia assay

Vero E6 cells were seeded in a 10 cm cell culture dish to reach 50-60% confluency after 24hr. Cells were transfected with 5 µg plasmid expressing SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein (BEI resources NR-52514) using Lipofectamine 2000 transfection reagent (Invitrogen, 11668019), as per manufacturer's instructions. After 24hr, cells were trypsinized and mixed with equal number of normal un-transfected Vero E6 cells to form a homogenous cell suspension. These cells were then seeded in a 24 well-cell culture dish containing glass coverslips, at a density of 1,00,000 cells per well. After 1hr, cells were treated with 0.25, 0.5, 1 and 2mM PA in triplicates, and incubated at 37°C, 5% CO₂. Non-treated cells and normal un-transfected Vero E6 cells serves as positive and negative controls respectively. After 24hr incubation, the cell culture plate was placed on ice to arrest endocytosis. Cells were then washed once with cold PBS and incubated with 10µg/mL Wheat Germ Hemagglutinin

(WGA) (Invitrogen, W11261) for 3 min, after which cells were fixed with 4% PFA for 10 min. This was followed by incubation of cells in PBS containing 0.1 µg/mL DAPI (Sigma Aldrich, D9542) for 10 min to label nuclei. Finally, cells were washed with PBS and the coverslips were mounted on glass slides using ProLong Diamond Antifade Mountant (Invitrogen, P36970).

- 5 Cells were imaged using an EVOS M5000 fluorescence microscope and the area of syncytia across different conditions were quantified by drawing ROIs using Imagej/Fiji.

Coxsackie and Rotavirus infections

- [00127] Coxsackie virus B3 infection: To study early effects of PA, HeLa cells were pre-treated for 3hr, infected with 10 MOI CVB3, and collected at 3hr post infection. Alternatively,
10 cells were infected and treated simultaneously (T0) and collected after 3hr. Also, a mixture of virus and drug incubated for 1hr (1hr PA+Virus) was used for infection to test the effects of PA on virus particles. No additional drug was added here post infection. Expression levels of VP1 protein was then detected by western blot analysis.

- [00128] Rotavirus RRV infection: A working concentration of Rota virus was prepared by
15 diluting the virus stock 2-fold with complete DMEM containing a final concentration of 2 µg/mL TPCK trypsin. The mixture was incubated at 37°C for 30 min and further diluted 2-fold in DMEM without serum. This mixture was then used to infect HEK cells that were pre-treated for 3hr with 2mM PA. A volume of 100 µL per well, in a 24 well plate was used for 1hr adsorption, after which the wells were topped up with 400 µL serum free media containing PA.
20 After 12 hr, cells were fixed with 4% formalin and immunolabeled with primary mouse anti VP6, and anti-mouse secondary Alexa Fluor 488 antibodies to detect virus infected cells by IFA.

Influenza virus membrane fusion assay

- [00129] Virus labelling: IAV particles were labelled using Octadecyl Rhodamine B Chloride
25 (R18) as reported earlier, with minor modifications (Hoekstra et al., 1984). A total volume of 1mL PR8 wild type virus (2×10^9 PFU/mL, titrated by plaque assay) was centrifuged at 2.5xg for 5 min to remove any debris, and placed on ice. R18 dye was added to the virus at 20 µM final concentration while simultaneously subjecting to continuous vortexing for 2 min, followed by which the virus-dye mixture was incubated for 60 min on a rocker at RT. After a
30 further 60 min incubation ice, the preparation was centrifuged at 25,000xg for 3hr at 4°C to remove unbound dye. Finally, the concentrated R18 labelled virus preparation was carefully

removed from the tube and re-suspended in 200µL NTC buffer (100 mM NaCl, 20 mM Tris-HCl pH 7.4, 5 mM CaCl₂).

[00130] Membrane fusion assay: The methodology for detection of IAV membrane fusion in endosomes was adapted from a previously reported protocol, with few modifications (Hoffmann et al., 2018). Briefly, MDCK cells in suspension were pre-treated/not for 3hr with 2mM PA, 10µM ammonium chloride (NH₄Cl) or 10µM Chloroquine (CQ) at 37°C. Cells were then washed with ice cold PBS and infected with 10MOI R18 labelled virus in OptiMEM containing 1µg/mL TPCK trypsin, and placed on ice. Post 1hr adsorption, cells were transferred to a pre-chilled opaque flat bottom 96-well cell culture plate (136101, Nunc) and placed in a TECAN Infinite 200-PRO multiplex reader pre-set at 37°C. Fluorescence intensity measurements (Ex 560/Em 590) were recorded at every 5 min interval for up to 90 min.

Characterizing effects of PA on endocytosis

[00131] Transferrin uptake assay: A549 cells in a 24 well dish were treated or not with 2mM PA for 2hr followed by washing of cells with PBS and starvation for 1hr in the presence of DMEM without FBS for 1hr. Cells were then washed and incubated with 25µg/mL Transferrin Alexa Fluor 647 Conjugate (T23366, Invitrogen) for 1hr. PA was present during the entire course of experiment. Finally, cells were washed twice with PBS, trypsinized and re-suspended in PBS containing 0.03% BSA for analysis in a Cytoflex flow cytometer. Results were analyzed using CytExpert software.

[00132] Localization of transferrin labelled vesicles: Vero cells were seeded on glass coverslips in a 12 well dish to reach 70-80% confluency next day. After 3hr treatment/not with 2mM PA, cells were washed once with ice cold PBS and the plate was placed on ice for 10 min before incubating with OptiMEM containing PR8 wild type virus (100 MOI) and 25µg/mL Transferrin 647 (Tf-647) for 1hr on ice. Cells were washed twice with PBS and the plate moved to 37°C. After a 15 min chase, cells were fixed with 4% PFA, labelled with anti influenza virus HA antibody (PY102) followed by anti-mouse Alexa 488 secondary antibody to label the virus particles. Nuclei were labelled using 0.1µg/mL DAPI. Images were acquired using a Zeiss LSM-880 Multiphoton microscope.

[00133] The dispersion of transferrin labelled vesicles from perinuclear region to cell periphery was quantified by drawing region of interests (ROIs) up to 20µm away from the nuclei. The fluorescence intensity of Tf-647 labelled vesicles was then measured along this distance using ImageJ/Fiji.

Drug cytotoxicity assay

[00134] A549 cells were seeded in 96-well cell culture dishes and 24hr later treated with 0.02, 0.2, 2, and 20mM PA in triplicates. Cells were then incubated at 37°C, 5% CO₂, and cytotoxicity was measured at 12, 24, 36, 48, 60, and 72hr post-treatment using AlamarBlue™
5 Cell Viability Reagent (DAL 1025, Thermo Fisher) as per manufacturer's instructions.

[00135] Similarly, cytotoxicity assay in MDCK cells measured at 48hr post-treatment was done using 0.2, 0.5, 1, and 2mM PA, in parallel with the multicycle IAV infection experiment mentioned below.

IAV time of addition assay

10 [00136] A549 cells were seeded in 24-well cell culture plates containing (or not) glass coverslips to reach 70-80% confluency the next day. For infection, cells were washed once with warm PBS and incubated with 100µL per well PR8 WT virus (2 MOI) diluted in OptiMEM. The plates were tilted at every 10 min to ensure even distribution of inoculum. After 1hr adsorption, the medium in wells were topped up with 400µL OptiMEM. Effects of PA on
15 early and late events during IAV infection was studied at 3 and 9hr time points p.i, respectively. In the former, cells were pre-treated with 2mM PA for 3hr, infected and collected at 3hr post infection. Alternatively, PA treatment was done only at 6hr post infection and cells were harvested after a further 3hr incubation period. Direct effect of the drug on virus particles was studied by incubating virus inoculum in OptiMEM containing 2mM PA at 37°C for 60 min,
20 followed by which the virus-drug mixture was used to infect cells as mentioned above. Post 1hr adsorption, the medium was topped up with 400µL OptiMEM without drug. In all cases, cells were harvested for both IFA and western blot analysis.

[00137] Immunofluorescence assay: Cells on glass coverslips were washed once with PBS, fixed with 4% PFA for 10 min and permeabilized for 10min with PBS containing 1% Tween-
25 20. Cells were then washed and incubated in blocking buffer (PBS with 0.3% Tween 20, 2% BSA) for 1hr. Overnight incubation with primary antibody Anti-mouse Influenza virus NP (HT103) diluted in blocking buffer was followed by washing and incubation with Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (A11001, Invitrogen) in blocking buffer containing 0.1µg/mL DAPI (D9542, Sigma). Finally, cells were
30 incubated with PBS containing 50mM ammonium chloride for de-quenching, washed, and the cells on coverslips were mounted on glass slides using ProLong™ Diamond Antifade Mountant (Molecular Probes, P36961). Images were acquired using an EVOS M5000 Imaging

system. Quantification of NP positive cells relative to the total number of DAPI positive cells in 5 different fields was performed using ImageJ/Fiji software.

[00138] Western Blot: Cells were washed with 1x PBS (162528, MP Biomedicals), lysed with 1X Laemmli buffer (1610747, BIO-RAD), and heated at 95°C for 10 min. Cell lysates were then subjected to standard SDS-PAGE and separated proteins were transferred onto a PVDF membrane (IPVH00010, Immobilon-P; Merck). The membrane was incubated in blocking buffer containing 5% Skimmed milk (Sigma-Aldrich, 70166) in 1xPBS containing 0.05% Tween 20 (P1379, Sigma-Aldrich) (1xPBST) for 2hr with slow rocking at room temperature (RT). Primary antibody Anti-mouse Influenza virus NP (HT103) incubation in blocking buffer was done for 14hr at 4°C with gentle rocking, after which the membrane was washed with 1X PBST and incubated for 2hr with secondary antibody Goat Anti-Mouse IgG - H&L Polyclonal Antibody, HRP conjugated (Abcam, ab6789) in blocking buffer at RT. After a further wash with 1X PBST, the blots were developed using Clarity Western ECL Substrate (Bio-Rad, 1705061).

15 SARS CoV-2 time of addition assay

[00139] VeroE6 and HEK ACE2 cells were seeded in 24-well cell culture plates containing glass coverslips to reach 70-80% confluency the next day. For infection, cells were washed once with warm PBS and incubated with 100µL per well 10 MOI SARS CoV-2 diluted in complete DMEM. The plates were tilted at every 10 min to ensure even distribution of inoculum. After 1hr adsorption, the media in wells were topped up with 400µL OptiMEM. Effects of PA on early and late events during SARS CoV-2 infection was studied at 3 and 9hr time points p.i, respectively. In the former, cells were pre-treated with 2mM PA for 3hr, infected and collected at 3hr post infection. Alternatively, cells were infected and treated simultaneously (T0) and collected after 3hr. The drugs effect on late events was studied by treating cells only during 6hr post infection, after which cells were harvested after 3hr. Once added, PA was present in the medium throughout the remaining duration of experiment. In all cases, cells were harvested for both IFA and western blot analysis.

[00140] The antibodies used for IFA included SARS-CoV-2 spike primary antibody (GTX632604, GeneTex) and goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen, A-11001). Quantification of spike positive cells was done using ImageJ/Fiji.

[00141] Western blot analysis of viral proteins used Polyclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein (BEI, NR-52947) and Goat Anti-Rabbit IgG - H&L Polyclonal antibody, HRP Conjugated (Abcam, ab6721).

5 Transmission Electron Microscopy

[00142] PR8 WT virus of stock titer 2×10^9 PFU/mL made in chicken eggs was passed through 0.45 μ m syringe filter and concentrated by ultracentrifugation at 25,000xg for 2hr at 4°C. The concentrated virus prep was then divided into three parts incubated with (a) 2mM Picolinic acid (b) Positive control – 0.01% TritinX100 and (c) Negative control - distilled water. Aliquots (2-3 μ L) of the virus samples were applied to a Formvar/carbon covered copper grid (Ted Pella, 01813,) which was hydrophilized by glow discharging at 8 W for 60 s directly before use. After 2 min, excess sample was removed using Whatman filter paper. 5 μ L of negative stain 2% uranyl acetate (Ted Pella, 19481) was added on to the grid and incubated for 40 secs, after which excess stain was removed. Negative staining step was repeated for 3 times and grid was air-dried for 10min before imaging. The grids were imaged using a Talos L120C transmission electron microscope equipped with a LaB6 electrode operating at an acceleration voltage of 120 kV. Images of the virus were recorded using a 4k Å~ 4k Ceta CMOS camera.

Mycobacteria and TM4 bacteriophage experiments

[00143] Bacterial culture and passage: Primary Mycobacterium smegmatis (mc2 155) (a kind gift from Prof. Deepak Saini, Indian Institute of Science) was grown in Middlebrook 7H9 broth (Merck, M0178) supplemented with Glycerol (Fisher scientific, Q24505), ADC (HiMedia, FD019), and 0.1% v/v Tween 80 (Fisher Scientific, YBP338500). A log phase primary culture was inoculated into a secondary culture without Tween-80 and supplemented with 2mM CaCl₂ (Fisher scientific, Q12135) to promote efficient infection of phages.

[00144] Bacteriophage: TM4 mycobacteriophage was amplified in M. smegmatis and phage enumeration was done using the soft agar overlay technique as reported by Kalapala et al (Kalapala et al., 2020).

[00145] Bacterial toxicity assay: PA stock solution of 1M concentration was prepared in sterile deionized water and diluted to obtain different concentrations (1mM, 5mM, 10mM, 20mM, and 40mM), in a 48- well plate. A total of 2×10^5 cells of M. smegmatis were added to each of the wells. The 48-well plate was placed in a rotary shaker incubator at 37°C for 24 h. Readings were taken periodically using a Tecan Spark multi-mode plate reader at 600 nm.

[00146] Effect of drug on TM4 mycobacteriophage: To study the effect of the drug on TM4 phage growth and activity, 7H9 broth supplemented with ADC and CaCl₂ was prepared and inoculated with 100 µL of log-phase secondary bacterial culture (OD 1 – 2) per 5mL of the media. 1mM of the drug was added to culture tubes at the appropriate time (either at the start
 5 of the experiment or 3hr before adding the phage in the mid-log phase). The cultures were then incubated at 37°C with rotary shaking at 180 pm. For phage-treated samples, a 10 MOI TM4 mycobacteriophage was added at a specified interval of the mid-log phase. For optical density (OD) measurements, 100 µL of bacterial culture at various time intervals was diluted 10 times in media and pipetted several times to obtain a uniform cell suspension. Readings were taken
 10 using a spectrophotometer (Jenway 7205 UV/Visible Spectrophotometer) at 600 nm against a media blank.

SARS CoV-2 infection studies in the hamster model

[00147] All animal experiments involving SARS CoV-2 infection were performed in 10–12-week-old mixed-gender Syrian golden hamsters (Biogen Laboratory Animal Facility
 15 Bengaluru, India). Males and female hamsters were housed separately in individually ventilated cages (IVC) maintained at 23±1°C temperature and 50±5% relative humidity, given access to standard pellet feed and water ad libitum, and maintained on a 12-hour day/night light cycle at the Viral Biosafety level-3 facility, Indian Institute of Science. An overdose of Ketamine (Bharat Parenterals Limited) and Xylazine (Indian Immunologicals Ltd) was used to
 20 sacrifice animals upon completion of the experiment. Experimentally, hamsters under intraperitoneal (IP) Ketamine (150mg/kg) (Bharat Parenterals Limited) and Xylazine (10mg/kg) (21, Indian Immunologicals Ltd) anesthesia were challenged intranasally with 105 plaque forming units (PFU) SARS CoV-2 in 100µL PBS. Two dosage regimens and routes of drug administration were followed for the treatment of animals. The prophylactic treatment
 25 used administration of 20mg/kg/day PA via oral or IP route during -3, -2, and -1 day before infection and therapeutic dosage (oral/IP) involved administering 20mg/kg/day PA during 1, 2 and 3-day post-infection (dpi). A total volume of 200µL PA dissolved in PBS was used for both oral and IP routes of administration. Total lungs were harvested, weighed, and processed for histopathological analysis. One portion was used for RNA extraction using Trizol and
 30 subsequent viral RNA copy number estimation by qRT PCT as described previously.

Histopathology of hamster Lung tissue:

[00148] Lung tissue samples were fixed in 4% paraformaldehyde (PFA), embedded in paraffin blocks and tissue sections of 4-6µm thickness made using a microtome. The sections were then

stained with Hematoxylin and Eosin and examined by light microscopy as previously described (Chan et al., 2020). Clinical scoring was done based on three different criteria namely: Alveolar edema; vascular and perivascular infiltration; alveolar thickening and infiltration. Scoring was done based on severity on a scale of 1-4 (1-mild, 2-moderate, 3-severe, 4-very severe).

CLAIMS

1. A method for inhibiting entry of a virus into a host cell, comprising contacting the host cell with picolinic acid or a salt or derivative thereof.
2. The method of claim 1, wherein the virus is an enveloped virus.
- 5 3. The method of claim 2, wherein the enveloped virus is SARS-CoV-2, parainfluenza, influenza, Japanese encephalitis virus, Zika virus, or a flavivirus.
4. The method of claim 1, wherein the virus is a syncytium-forming virus.
5. The method of claim 4, wherein the syncytium-forming virus is selected from Coronaviridae (e.g., SARS-CoV-2, MERS, SARS-CoV etc.), Herpesviridae (HSV, HCMV etc.), Paramyxoviridae (Nipah, Hendra, Measles, RSV etc.), Retroviridae
10 (HIV, HTLV etc.), Hepatitis C Virus, Ebola, Sendai, Reovirus (e.g., Orthoreoviruses and Aquareoviruses).
6. The method of any one of claims 1-5, wherein the salt is selected from zinc picolinate, chromium picolinate, iron picolinate, sodium picolinate, or a combination thereof.
- 15 7. The method of any one of claims 1-5, wherein the derivative is fusaric acid or a compound comprising substitutions at the 3, 4, 5 and/or 6 positions of picolinic acid.
8. The method of any one of claims 1-7, wherein the host cell is a mammalian cell, an avian cell, or a plant cell.
9. A method for treating or preventing a viral infection in a subject, comprising
20 administering to the subject picolinic acid or a salt or derivative thereof.
10. The method of claim 9, wherein the viral infection is caused by an enveloped virus.
11. The method of claim 10, wherein the enveloped virus is SARS-CoV-2, parainfluenza, influenza, Japanese encephalitis virus, Zika virus or a flavivirus.
12. The method of claim 9, wherein the viral infection is caused by a syncytium-forming
25 virus.
13. The method of claim 12, wherein the syncytium-forming virus is selected from Coronaviridae (e.g., SARS-CoV-2, MERS, SARS-CoV etc.), Herpesviridae (HSV, HCMV etc.), Paramyxoviridae (Nipah, Hendra, Measles, RSV etc.), Retroviridae

(HIV, HTLV etc.), Hepatitis C Virus, Ebola, Sendai, Reovirus (e.g., Orthoreoviruses and Aquarecoviruses).

14. The method of any one of claims 9-13, wherein the salt is selected from zinc picolinate, chromium picolinate, iron picolinate, sodium picolinate, or a combination thereof.
15. The method of any one of claims 9-13, wherein the derivative is fusaric acid or a compound comprising substitutions at the 3, 4, 5 and/or 6 positions of picolinic acid.
16. The method of any one of claims 9-15, wherein the picolinic acid or the salt or derivative thereof is administered via a route of administration selected from the group consisting of oral, parenteral, intranasal, inhalation, nebulization, and topical.
17. The method of claim 16, wherein the route of administration is oral.
18. The method of claim 16, wherein the route of administration is intranasal.
19. The method of any one of claims 9-18, wherein about 3 mg to about 100 mg of picolinic acid or the salt or derivative thereof is administered to the subject per kilogram of body weight per day.
20. The method of any one of claims 9-19, wherein the subject is a mammal, bird, or plant.
21. Picolinic acid or a salt or derivative thereof for use in inhibiting entry of a virus into a host cell.
22. Picolinic acid or a salt or derivative thereof for use as claimed in claim 21, wherein the virus is an enveloped virus.
23. Picolinic acid or a salt or derivative thereof for use as claimed in claim 22, wherein the enveloped virus is SARS-CoV-2, parainfluenza, influenza, Japanese encephalitis virus, Zika virus, or a flavivirus.
24. Picolinic acid or a salt or derivative thereof for use as claimed in claim 21, wherein the virus is a syncytium-forming virus.
25. Picolinic acid or a salt or derivative thereof for use as claimed in claim 21, wherein the syncytium-forming virus is selected from Coronaviridae (e.g., SARS-CoV-2, MERS, SARS-CoV etc.), Herpesviridae (HSV, HCMV etc.), Paramyxoviridae

- (Nipah, Hendra, Measles, RSV etc.), Retroviridae (HIV, HTLV etc.), Hepatitis C Virus, Ebola, Sendai, Reovirus (e.g., Orthoreoviruses and Aquareoviruses).
26. Picolinic acid or a salt or derivative thereof for use as claimed in any one of claims 21-25, wherein the host cell is a mammalian cell, an avian cell, or a plant cell.
- 5 27. Picolinic acid or a salt or derivative thereof for use as a medicament for treating or preventing a viral infection in a subject.
28. Picolinic acid or a salt or derivative thereof for use as claimed in claim 27, wherein the viral infection is caused by an enveloped virus.
- 10 29. Picolinic acid or a salt or derivative thereof for use as claimed in claim 28, wherein the viral infection is a SARS-CoV-2, parainfluenza, influenza, Japanese encephalitis virus, Zika virus, or a flavivirus infection.
30. Picolinic acid or a salt or derivative thereof for use as claimed in claim 27, wherein the viral infection is caused by a syncytium-forming virus.
- 15 31. Picolinic acid or a salt or derivative thereof for use as claimed in claim 30, wherein the syncytium-forming virus is selected from Coronaviridae (e.g., SARS-CoV-2, MERS, SARS-CoV etc.), Herpesviridae (HSV, HCMV etc.), Paramyxoviridae (Nipah, Hendra, Measles, RSV etc.), Retroviridae (HIV, HTLV etc.), Hepatitis C Virus, Ebola, Sendai, Reovirus (e.g., Orthoreoviruses and Aquareoviruses).
- 20 32. Picolinic acid or the salt or derivative thereof for use as claimed in any one of claims 21-31, wherein the salt is selected from zinc picolinate, chromium picolinate, iron picolinate, sodium picolinate, or a combination thereof.
33. Picolinic acid or the salt or derivative thereof for use as claimed in any one of claims 21-31, wherein the derivative is fusaric acid or a compound comprising substitutions at the 3, 4, 5 and 6 positions of picolinic acid.
- 25 34. Picolinic acid or the salt or derivative thereof for use as claimed in any one of claims 27-33, wherein the medicament is administered via a route of administration selected from the group consisting of: oral, parenteral, intranasal, inhalation, nebulization, and topical.
- 30 35. Picolinic acid or the salt or derivative thereof for use as claimed in any one of claims 27-33, wherein the medicament is administered orally or intranasally.

36. Picolinic acid or the salt or derivative thereof for use as claimed in any one of claims 27-35, wherein the medicament comprises 1 to 500 mg of picolinic acid or the salt or derivative thereof in a unit dose.
37. Picolinic acid or the salt or derivative thereof for use as claimed in any one of claims 27-36, wherein the subject is a mammal, bird, or plant.
38. An oral pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient.
39. A parenteral pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient.
40. An intranasal pharmaceutical composition comprising picolinic acid or a salt or derivative thereof and a pharmaceutically acceptable excipient.
41. A dietary supplement comprising picolinic acid or a salt or derivative thereof.
42. A horticultural or agricultural composition comprising picolinic acid or a salt or derivative thereof and a horticulturally or agriculturally acceptable excipient.
43. A method for treating a viral infection in plants comprising, contacting a plant cell with picolinic acid or a salt or derivative thereof.
44. The method of claim 43, wherein the viral infection is caused by a virus from a virus family selected from the group consisting of Geminiviridae (e.g., Cassava Mosaic Virus, Maize streak virus); Caulimoviridae (e.g., Banana streak virus, Rice Tungro Bacilliform virus); Potyviridae (e.g., Sugarcane mosaic virus, Maize dwarf mosaic virus, Sweet potato feathery mottle virus); Tombusviridae (e.g., Barley yellow dwarf viruses); Bromoviridae (e.g., Cucumber mosaic virus); and Nanoviridae (e.g., Banana bunchy top virus).




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5A

B




FIG. 5B




FIG. 6




FIG. 7




FIG. 7 (cont'd)




FIG. 8




FIG. 8 (cont'd)




FIG. 8 (cont'd)




FIG. 9




FIG. 9 (cont'd)






FIG. 9 (cont'd)






FIG. 10 (cont'd)




FIG. 10 (cont'd)




FIG. 11




FIG. 11 (cont'd)




FIG. 12



F**G**

FIG. 12 (cont'd)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2022/050463

A. CLASSIFICATION OF SUBJECT MATTER
C07D213/81, A61P31/12 Version=2022.01

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer, IPO Internal Database

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FERNANDEZ-POL J A ET AL.: "ANTIVIRAL, CYTOTOXIC AND APOPTOTIC ACTIVITIES OF PICOLINIC ACID ON HUMAN IMMUNODEFICIENCY VIRUS-1 AND HUMAN HERPES SIMPLEX VIRUS-2 INFECTED CELLS", ANTICANCER RESEARCH, VOL. 21, NO. 6A, NOV-DEC 2001 abstract; pages 3773-3776	21-42
Y	US20100015174A1 (JOSE ALBERTO FERNANDEZ-POL AND SEBASTIAN FERNANDEZ-POL, CHESTERFIELD, MO [US]), 21 JANUARY 2010 (21/01/2010) abstract; para [0038], examples, claims 1-15	21-42
Y	WO1997024121A1 (FERNANDEZ-POL J A [US]) 10 JULY 1997 (10/07/1997) abstract; examples, fig. 1-5, claims 1-41	21-42
Y	WO2002020486A2 (NOVACTYL INC. [US]) 14 MARCH 2002 (14/03/2002) abstract; examples, fig. 1-13, claims 1-20	21-42
Y	SHARMA R ET AL.: "INHIBITION OF CHIKUNGUNYA VIRUS BY PICOLINATE THAT TARGETS VIRAL CAPSID PROTEIN",	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23-05-2022

Date of mailing of the international search report

23-05-2022

Name and mailing address of the ISA/

Indian Patent Office
Plot No.32, Sector 14, Dwarka, New Delhi-110075
Facsimile No.

Authorized officer

Chanchal Kumar Malav

Telephone No. +91-1125300200

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2022/050463

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-20, 43, 44
because they relate to subject matter not required to be searched by this Authority, namely:
The subject matter of claims 1-20, 43, and 44 relates to a method for treatment of the human or animal body by surgery or therapy, which does not require an international search by the International Searching Authority in accordance with PCT Article 17(2)(a)(i) and [Rule 39.1(iv)]1.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2022/050463

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	VIROLOGY, VOL. 498, NOVEMBER 2016 abstract; pages 265-276	21-42

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IB2022/050463

Citation	Pub.Date	Family	Pub.Date
US 20100015174 A1	21-01-2010	AR 072542 A1	08-09-2010
WO 1997024121 A1	10-07-1997	US 5767135 A	16-06-1998
		EP 0869789 B1	23-11-2005
		AU 1349597 A	28-07-1997
WO 2002020486 A2	14-03-2002	US 6579891 B1	17-06-2003
		AU 8878801 A	22-03-2002